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ABSTRACT OF DISSERTATION 
DISRUPTIONS IN THE REGULATION OF EXTRACELLULAR GLUTATMATE AFTER 
DIFFUSE BRAIN INJURY  
By 
Jason Michael Hinzman 
Glutamate, the predominant excitatory neurotransmitter in the central nervous 
system, is involved in almost all aspects of neurological function including cognition, 
motor function, memory, learning, decision making, and neuronal plasticity. For normal 
neurological function, glutamate signaling must be properly regulated. Disrupted 
glutamate regulation plays a pivotal role in the acute pathophysiology of traumatic brain 
injury (TBI), disrupting neuronal signaling, initiating secondary injury cascades, and 
producing excitotoxicity. Increases in extracellular glutamate have been correlated with 
unfavorable outcomes in TBI survivors, emphasizing the importance of glutamate 
regulation.  
The aim of this thesis was to examine disruptions in the regulation of extracellular 
glutamate after experimental TBI. In these studies, we used glutamate-sensitive 
microelectrode arrays (MEAs) to examine the regulation of extracellular glutamate two 
days after diffuse brain injury. First, we examined which brain regions were vulnerable to 
post-traumatic increases in extracellular glutamate. We detected significant increases in 
extracellular glutamate in the dentate gyrus and striatum, which correlated to the severity 
of brain injury. Second, we examined the regulation of extracellular glutamate by 
neurons and glia to determine the mechanisms responsible for post-traumatic increases 
in extracellular glutamate. In the striatum of brain-injured rats, we detected significant 
disruptions in release of glutamate by neurons and significant decreases in the removal 
of glutamate from the extracellular space by glia. Third, we examined if a novel 
therapeutic strategy, a viral-vector mediated gene delivery approach, could improve the 
regulation of extracellular glutamate. Infusion of an adeno-associated virus expressing a 
glutamate transporter into the rat striatum produced significant improvements in 
glutamate clearance, identifying a novel strategy to reduce excitotoxicity. Lastly, we 
examined the translational potential of MEAs as novel neuromonitoring device for clinical 
TBI research. Overall, these studies have demonstrated the translational potential of 
MEAs to aid in the diagnosis and treatment of TBI survivors. 
 
KEYWORDS: midline fluid percussion injury, amperometry, excitatory amino acid 
transporters 
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Chapter One: Introduction 
 
Traumatic Brain Injury 
Recent estimates indicate that traumatic brain injury (TBI) produces 50,000 
deaths, 235,000 hospitalizations, and 1.1 million visits to the emergency department 
annually in the United States. Nationally, the top three causes of TBI are falls (28%), 
motor vehicle crashes (20%), and being struck by an object or person (19%) (Corrigan, 
et al. 2010). TBI is a heterogeneous disorder producing a wide range of symptoms 
based on the severity of the injury. The Glasgow coma scale (GCS) was developed to 
reliably classify the severity of a TBI based on the patient’s eye, verbal, and motor 
responses with a total GCS score of (≥13) for mild injury, (9-12) for moderate injury, and 
(≤8) for severe injury (Table 1.1) (Narayan, et al. 2002). TBI results in various anatomical 
changes within the central nervous system including hemorrhage (subarachnoid and 
intraventricular), hematoma (epidural, subdural, and parenchymal), diffuse axonal injury, 
and contusion (Saatman, et al. 2008). Presently, there are no approved therapeutics for 
the treatment of TBI, instead current medical care focuses on maintaining proper 
physiological parameters such as intracranial pressure and blood pressure (Wang, et al. 
2006). 
Traumatic brain injury contains two distinct pathophysiological processes, 
primary injury and secondary injury (McIntosh, et al. 1996). Primary injury is the result of 
mechanical forces producing tissue deformation at the time of injury that damages blood 
vessels, shears axons, and produces cellular damage (Reilly and  Bullock 1997, Gaetz 
2004). Secondary injury, a consequence of the primary tissue damage, propagates 
damage through complex biochemical and cellular pathways (McIntosh, et al. 1996, 
Reilly and  Bullock 1997). Secondary injury, which occurs in the hours to days after 
injury, is the target of therapies to reduce or limit damage to improving outcomes in TBI 
survivors (Bullock, et al. 1995, Myseros and  Bullock 1995, Reilly and  Bullock 1997). 
Recent evidence suggests that TBI is more than a single event; instead, it involves a 
complex disease process with the long term consequences including an increased risk 
for epilepsy, sleep disorders, neurodegenerative diseases, neuroendocrine disorders,  
psychiatric disorders, and reduced life expectancy (Masel and  DeWitt 2010). 
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Glutamate’s Role as a Neurotransmitter in the Central Nervous System 
Glutamate, the predominant excitatory neurotransmitter in the central nervous 
system, is involved in almost all aspects of neurological function including cognition, 
motor function, memory, learning, decision making, and neuronal plasticity (McEntee 
and  Crook 1993). In nerve terminals, glutamate is synthesized from multiple sources for 
neurotransmission. Glutamate can be synthesized from glucose via the Krebs cycle, 
transamination of α-oxoglutarate by alanine transaminase, and conversion of glutamine 
by glutaminase (Cooper, et al. 2003). High concentrations of glutamate are packaged 
into synaptic vesicles by vesicular glutamate transporters (vGluTs) using a proton-
dependent electrochemical gradient across the vesicle membrane to transport glutamate 
against the concentration gradient (Takamori 2006). Glutamate is released into the 
extracellular space by two mechanisms. First, classical release of glutamate by neurons 
involves the opening of voltage-gated calcium channels after neuronal depolarization, 
permitting calcium influx into the nerve terminal. Calcium influx induces membrane 
fusion of the vesicles and exocytosis of glutamate into the extracellular space (Danbolt 
2001, Cooper, et al. 2003). Second, glutamate is released into the extracellular space 
via carrier mediated exchange with other amino acids (Jabaudon, et al. 1999, Jensen, et 
al. 2000). Once in the extracellular space glutamate binds to ionotropic and metabotropic 
glutamate receptors for signal propagation (Fig 1.1).  
There are three major types of ionotropic glutamate receptors (iGluRs), named 
after the agonist that would selectively activate them: N-methyl-D-aspartate (NMDA), α-
amino-3-hydroxy-5-methyl-4-isoazolepropionic acid (AMPA), and 2-carboxy-3-
carboxymethyl-4-isopropenylpyrrolidine (Kainate, KA) (Table 1.2). The iGluRs are 
ligand-gated ion channels responsible for modulating post-synaptic excitability and 
plasticity (Kew and  Kemp 2005). AMPA and KA receptors are involved in fast excitatory 
neurotransmission; glutamate binding produces a conformational change in both 
receptors permitting sodium influx into the post-synaptic neuron (Greene and  
Greenamyre 1996). Compared to AMPA and KA receptors, the NMDA receptor requires 
multiple steps for activation. First, the NMDA receptor requires binding of two ligands, 
glutamate and glycine. Second, because the NMDA receptor is a voltage-sensitive ion 
channel, it requires depolarization to release the magnesium block and permit calcium 
influx. Glutamate binding to AMPA and KA receptors permits sodium influx into the cell, 
responsible for depolarizing the post-synaptic neuron and removing the magnesium 
block. Binding of glutamate and glycine, while the post-synaptic neuron is in a 
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depolarized state, will then open the ion channel of the NMDA receptor permitting 
calcium influx (Gardoni and  Di Luca 2006). 
There are a total of eight metabotropic glutamate receptors (mGluRs), organized 
into three groups (Table 1.3). mGluRs are G-protein coupled receptors using second 
messenger responses for signal transduction. mGluRs regulate the release of glutamate, 
post-synaptic excitability, packaging of glutamate into vesicles, and uptake of glutamate 
from the extracellular space (Schoepp 2001, Swanson, et al. 2005). Since mGluRs use 
secondary messenger systems for signal propagation, signaling is generally slower 
compared to activation of iGluRs. mGluRs contain seven alpha-helical transmembrane 
domains with a ligand binding site located on the extracellular N-terminus (Kew and  
Kemp 2005). Group I (mGluR1 and mGluR5) are excitatory localized on the post-synaptic 
terminals of glutamatergic neurons. Group II (mGluR2 and mGluR3) receptors are 
inhibitory with mGluR2 localized primarily on pre-synaptic glutamatergic terminals, while 
mGluR3 is expressed on glial as well as pre- and post-synaptic glutamatergic neurons. 
Group III (mGluR4, mGluR6, mGlu7 and mGluR8) are inhibitory with mGluR4 and mGluR7 
receptors localized pre- and post-synaptically (Schoepp 2001) (Refer to Table 1.2 for 
localization and function of mGluRs).   
For normal neurological function, extracellular concentrations of glutamate must 
be properly regulated. Appropriate activation of glutamate receptors requires the 
extracellular concentration of glutamate to remain low, producing a high signal-to-noise 
ratio during synaptic release of glutamate. Since there are no extracellular enzymes to 
degrade glutamate, low concentrations of extracellular glutamate are maintained by the 
uptake of glutamate via five high affinity sodium-dependent excitatory amino acid 
transporters (EAATs) (EAAT1, GLAST) (EAAT2, GLT-1), (EAAT3, EAAC), EAAT4, and 
EAAT5 (Danbolt 2001)(Table 1.4). Glutamate uptake is an electrogenic process using 
the negative membrane potential maintained by the sodium/potassium adenosine 
triphosphatase to transport glutamate. Uptake of glutamate by the EAATs requires both 
sodium and potassium ions; sodium for glutamate binding and potassium for glutamate 
transport. During glutamate transport, one molecule of glutamate, three sodium ions, 
and one hydrogen ion are transported into the cell, while one potassium ion is 
transported out of the cell (Danbolt 2001). A majority (~90%) of glutamate uptake is 
performed by two glial transporters in the rat forebrain, GLAST and GLT-1 (Rothstein, et 
al. 1996, Tanaka, et al. 1997, Danbolt 2001).  
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Glutamate’s Role in the Pathophysiology of TBI 
While glutamate normally functions as an excitatory neurotransmitter, increases 
in extracellular glutamate can lead to excessive stimulation of glutamate receptors 
producing cell death by a mechanism termed “excitotoxicity” (Lucas and  Newhouse 
1957, Olney and  de Gubareff 1978). Excitotoxicity was described as a phenomenon 
whereby the excitatory action of glutamate becomes transformed into a 
neuropathological process that rapidly kills neurons (Olney and  de Gubareff 1978). 
Excitotoxicity involves the activation of complex biochemical and cellular pathways that 
produce prolonged depolarization of neurons, increased concentrations of intracellular 
calcium, and activation of enzymatic and nuclear mechanisms of cell death (Doble 
1999). Increases in extracellular glutamate have been shown to play a pivotal role in the 
initiation and propagation of secondary brain injury (Fig 1.2). The mechanical forces of 
the primary brain injury compromise the blood-brain barrier and cellular membranes 
releasing glutamate into the extracellular space (Schmidt and  Grady 1993, Bullock, et 
al. 1998, Farkas, et al. 2006). Also, redistribution of ions from the primary injury creates 
a massive depolarization leading to neuronal release of glutamate (Katayama, et al. 
1990). The massive increase in extracellular glutamate at the initial time of injury has 
been well characterized in experimental models of traumatic brain injury (Faden, et al. 
1989, Katayama, et al. 1990, Nilsson, et al. 1990, Palmer, et al. 1993, Globus, et al. 
1995, Katoh, et al. 1997, Stoffel, et al. 1997, Matsushita, et al. 2000, Rose, et al. 2002, 
Stoffel, et al. 2002).  
The initial surge of glutamate at the time of injury leads to excessive activation of 
iGluRs and mGluRs, and increases glutamate uptake by the EAATs to restore the 
extracellular glutamate concentration. The above processes lead to increase ionic flux 
into the cell. First, increases in extracellular glutamate activate AMPA and KA receptors 
permitting sodium influx into the cell and depolarizing the cell (Greene and  Greenamyre 
1996). Second, depolarization opens voltage-sensitive calcium channels and removes 
the magnesium block from the NMDA receptor, which allows further calcium influx into 
the cell (Gardoni and  Di Luca 2006). Third, activation of Group I mGluRs by glutamate 
leads to the opening of voltage-gated calcium channel permitting calcium influx (Mao 
and  Wang 2002). Lastly, uptake of glutamate by the EAATs results in sodium influx into 
the cell (Danbolt 2001). To maintain ionic equilibrium in the cell, chloride ions passively 
diffuse into the cell along with water creating osmotic swelling of the cell. Cytoxic edema 
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directly contributes to raising the intracranial pressure (ICP), one of the most common 
sequelae of secondary brain injury (Marmarou 2004).  
To restore ionic equilibrium in the cell, the sodium-potassium pump actively 
transports sodium out of the cell.  Since the sodium-potassium pump is driven by the 
hydrolysis of adenosinetriphospate (ATP), reestablishing the ionic equilibrium can 
deplete ATP levels in the cell (Tavalin, et al. 1997). After TBI, there is an increase in 
glucose transport to facilitate glycolysis and ATP generation (Kawamata, et al. 1995). 
Restoring the ATP concentration through oxidative phophsorylation leads to 
mitochondrial dysfunction as the mitochondria attempt to maintain the energy supply 
(Sullivan, et al. 2005). Mitochondrial dysfunction leads to the production of reactive 
oxygen species (ROS) and oxidative damage that includes protein nitration and lipid 
peroxidation (Braughler and  Hall 1992, Hall, et al. 1994, Singh, et al. 2006). 
Mitochondrial dysfunction and oxidative damage are well established sequelae of 
secondary brain injury (Braughler and  Hall 1992, McIntosh, et al. 1996, Sullivan, et al. 
2005). Mitochondrial dysfunction in a state of increased glycolysis leads to anaerobic 
glycolysis and the production of lactate as an alternate energy supply. TBI produces 
significantly higher levels of lactate in the brain, with a correlation between lactate levels 
and reduced outcomes in TBI survivors (Reilly and  Bullock 1997, Makoroff, et al. 2005). 
A pivotal process in the secondary injury cascade is calcium influx into the cell, 
the ability of the cell to survive depends on the buffering capacity of the mitochondria 
and endoplasmic reticulum to sequester cytosolic calcium (Doble 1999).  If the cell is 
unable to buffer the calcium influx, calcium overload can trigger many irreversible 
neurotoxic cascades, including the uncoupling mitochondrial electron transfer from ATP 
synthesis, the activation and overstimulation of enzymes such as calpains and other 
proteases, protein kinases, nitric oxide synthase, calcineurins, and endonucleases 
(Nasr, et al. 2003, Arundine and  Tymianski 2004, Lifshitz, et al. 2004, Sullivan, et al. 
2005). The above processes lead to cellular damage and dysfunction, responsible for 
the activation of apoptotic/necrotic mechanisms of cell death (Nicholls and  Budd 2000, 
Sattler and  Tymianski 2000). Reducing or preventing increases in cytosolic calcium and 
the activation of neurotoxic cascades has been the therapeutic target of multiple 
compounds to provide neuroprotection and improved outcomes after TBI (Okonkwo, et 
al. 1999, Sullivan, et al. 2004, Geddes and  Saatman 2010, Saatman, et al. 2010).  
Increases in extracellular glutamate not only initiate secondary injury cascades, 
but the downstream consequences of secondary injury lead to further increases in 
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extracellular glutamate that amplify and propagate damage. First, increased ionic flux 
can depolarize neurons and enhance vesicular glutamate release. Second, structural 
damage to the cell can lead to a loss of membrane fidelity allowing glutamate to leak into 
the extracellular space (Yi and  Hazell 2006). Third, release of inflammatory cytokines 
can activate microglia, which release glutamate into the extracellular space via the 
glutamate/cystine exchanger (Barger, et al. 2007). Fourth, disruptions in the ionic 
equilibrium and oxidative damage to the EAATs can inhibit the ability of the EAATs to 
uptake glutamate from the extracellular space (Trotti, et al. 1998). Overall, increases in 
the release of glutamate and decreases in the ability to uptake glutamate can increase 
the extracellular concentrations of glutamate diffusing to nearby neurons amplifying and 
propagating secondary damage.  
Clinically, a multitude of studies have detected significant increases in 
extracellular glutamate levels in the days following injury with some reports correlating 
increases in extracellular glutamate with unfavorable  outcomes (Persson and  Hillered 
1992, Bullock, et al. 1995, Bullock, et al. 1998, Koura, et al. 1998, Vespa, et al. 1998, 
Yamamoto, et al. 1999, Reinert, et al. 2000, Hutchinson, et al. 2002, Hlatky, et al. 2004, 
Chamoun, et al. 2010, Lakshmanan, et al. 2010, Timofeev, et al. 2011a). Based on the 
large body of clinical evidence supporting a role for increased glutamate release and 
excessive glutamate receptor activation in pathophysiology of TBI, many compounds 
have been developed to modulate aspects of glutamate signaling. The NMDA receptor 
has been the primary therapeutic target to reduce excitotoxicity (Muir 2006). 
Unfortunately, NMDA antagonists have failed to reach their primary endpoints in 
randomized controlled trials in head-injured patients (Willis, et al. 2004). One of the 
major problems encountered with the NMDA antagonists trials were adverse effects that 
include hallucinations, catatonia, ataxia, nightmares, and memory deficits (Blanke and  
VanDongen 2009). 
 Unlike the clinical studies, multiple animals studies report increases in 
extracellular glutamate at the time of the injury, which returns to baseline concentrations 
within the first hour after injury (Faden, et al. 1989, Katayama, et al. 1990, Nilsson, et al. 
1990, Palmer, et al. 1993, Globus, et al. 1995, Katoh, et al. 1997, Stoffel, et al. 1997, 
Matsushita, et al. 2000, Rose, et al. 2002, Stoffel, et al. 2002). Since experimental TBI 
has failed to model glutamate dysregulation seen in the clinic, the role of glutamate 
excitotoxicity in the acute pathophysiology of TBI has been challenged and remains 
unclear (Carbonell and  Grady 1999, Obrenovitch 1999). All of the prior studies have 
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used microdialysis, a common method for neurochemical sampling in vivo. However, 
microdialysis suffers from methodological limitations that restrict the ability of 
microdialysis to sample glutamate near the synapse, due to poor spatial and temporal 
resolution and extensive damage from implantation of the probe (Obrenovitch, et al. 
2000, Borland, et al. 2005, Diamond 2005, Hillered, et al. 2005, Jaquins-Gerstl and  
Michael 2009). 
In this thesis, we will re-examine glutamate dysregulation in the acute 
pathophysiology of experimental brain injury using a novel technique, enzyme-based 
microelectrode arrays (MEAs). MEAs have improved upon some methodological 
limitations inherent to microdialysis allowing measures of extracellular glutamate closer 
to the synapses (Burmeister and  Gerhardt 2001, Burmeister, et al. 2002, Day, et al. 
2006, Hascup, et al. 2010). We will use MEAs to examine disruptions in the regulation of 
extracellular glutamate in brain regions that may be responsible for post-traumatic 
deficits in behavioral, cognitive, and motor function. The overall goal of this thesis is to 
examine the regulation of extracellular glutamate after a TBI, identify novel therapeutic 
targets to improve the regulation of extracellular glutamate, and examine possible 
therapeutic approaches to improve regulation of extracellular glutamate. 
 
 
Copyright © Jason Michael Hinzman 2012 
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Chapter One: Figures 
 
 
Figure 1.1 Schematic of a glutamate synapse 
  
Several aspects of glutamate neurotransmission are depicted in the diagram of a 
glutamate synapse. Glutamate is packaged into vesicles by vesicular glutamate 
transporters (vGluT). Glutamate is released in the extracellular space in a Ca2+-
dependent mechanism upon membrane depolarization. Glutamate can also be released 
from non-neuronal sources, such as the cystine/glutamate exchanger. Once in the 
extracellular space, glutamate propagates downstream signaling by binding to both 
metabotropic glutamate receptors (mGluRs) and ionotropic glutamate receptors 
(iGluRs). Glutamate is removed from the extracellular space by sodium-dependent, high 
affinity excitatory amino acid transporters (EAATs), regulating the extracellular glutamate 
concentration and activation of glutamate receptors. 
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Figure 1.2 Schematic and diagram depicting glutamate’s role in the initiation, 
propagation, and amplification of secondary brain injury 
  
Schematic (A) and diagram (B) depicting glutamate’s role in the complex biochemical 
and cellular pathways involved in secondary brain injury.  
 
 
 
Glutamate
Na+ Ca2+ Influx
Glutamate Receptor 
Activation
Glutamate Uptake
Na +/K+ Activity
Cellular  Swelling
ICP
ATP Depletion
Mitochondrial Stress
Activation of Proteases 
and Lipases
Protein, Enzyme,
and Membrane  Damage
Oxidative Damage
Free Radicals and 
Reactive Oxygen Species
Cellular Dysfunction/
Apoptosis/Necrosis
Cl- Influx
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Chapter One: Tables 
 
Table 1.1 Glasgow Coma Scale (GCS) 
 
 
Score 1 2 3 4 5 6 
Eyes Does not 
open eyes 
Opens eyes 
to painful 
stimuli 
Opens eyes 
to voice 
Opens eyes 
spontaneoulsy   
Verbal Does not 
make sound 
Incomprehen
sible sound 
Sounds 
inappropiate 
words 
Confused or 
disorinted 
Converses 
normally  
Motor Does not 
move 
Extension to 
painful stimuli 
Abnormal 
flexion to 
painful stimuli 
Flexion  
withrdrawl to 
painful stimuli 
Localizes 
painful 
stimuli 
Obeys 
commands 
 
 
 
 
 
 
Table 1.2  Ionotropic Glutamate Receptors  
 
 
NMDA AMPA Kainate 
Receptor 
Subunits 
NR1, NR2A, NR2B NR2C, 
NR2D NR3A, NR3B 
GluR1, GluR2, 
GluR3, GluR4 
GluR5, GluR6 
GluR7, KA-1 KA-2 
Signal 
Transduction 
Ca2+, Na+ Na+ (Ca2+) Na+ (Ca2+) 
Severity GCS (Total Score) 
Minor ≥ 13 
Moderate 9-12 
Severe ≥ 8 
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Table 1.3  Metabotropic Glutamate Receptors  
 
Receptor Localization Function 
G
ro
up
 I 
 
mGluR1 
 
Pre-synaptic 
Post-synaptic 
 
Enhances excitability 
Synaptic plasticity, LTP/LTD 
mGluR5 Post-synaptic and glia Synaptic plasticity, LTD 
G
ro
up
 II
  mGluR2 Pre-synaptic LTD 
mGluR3 Pre/Post-synaptic and glia Neurotropin release 
G
ro
up
 II
I 
mGluR4 Pre/Post-synaptic Motor learning 
mGluR6 Retina Visual acuity 
 
mGluR7 
Pre/Post-synaptic Autoreceptor 
mGluR8 Pre-synaptic Regulation of lateral perforant path 
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Table 1.4 Excitatory Amino Acid Transporters (EAATs) 
 
Human 
Nomenclature     
 
Rodent 
Nomenclature 
 
Localization 
EAAT1 
Glutamate aspartate 
transporter (GLAST) 
Astrocytes 
EAAT2 
Rat glutamate 
transporter (GLT-1) 
Astrocytes 
EAAT3 
Rabbit glutamate 
transporter (EAAC) 
Postsynaptic neurons 
EAAT4 
 Cerebellar Purkinje neurons 
(human) 
EAAT 5  Retina (human) 
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Preface to Chapter Two 
The aim of the experiments in Chapter Two was to examine if an experimental 
model of diffuse traumatic brain injury (TBI) produced post-traumatic disruptions in the 
regulation of tonic glutamate and potassium-evoked glutamate release in brain regions 
that may be responsible for post-traumatic deficits in behavioral, cognitive, and motor 
function. Using glutamate-sensitive microelectrode arrays (MEAs), I detected discrete 
regional changes in tonic glutamate and potassium-evoked glutamate release that were 
dependent on the severity of injury. In the end, I demonstrated that glutamate-sensitive 
MEAs were able to detect disruptions in the regulation of extracellular glutamate two-
days after diffuse brain injury. 
 
Chapter Two: Diffuse Brain Injury Elevates Tonic Glutamate Levels and  
Potassium-Evoked Glutamate Release in Discrete Brain Regions  
at Two Days Post-Injury: an Enzyme-Based Microelectrode Array Study 
 
Abstract 
Traumatic brain injury (TBI) survivors often suffer from a wide range of post-
traumatic deficits including impairments in behavioral, cognitive, and motor function. 
Regulation of glutamate signaling is vital for proper neuronal excitation in the central 
nervous system. Without proper regulation, increases in extracellular glutamate can 
contribute to the pathophysiology and neurological dysfunctions seen in TBI. In the 
present studies, enzyme-based microelectrode arrays (MEAs) that selectively measure 
extracellular glutamate at 2 Hz enabled the examination of tonic glutamate levels and 
potassium chloride (KCl)-evoked glutamate release in the prefrontal cortex, dentate 
gyrus, and striatum of adult male rats two days after mild or moderate midline fluid 
percussion brain injury. Moderate brain injury significantly increased tonic extracellular 
glutamate levels by 256% in the dentate gyrus and 178% in the dorsal striatum. In the 
dorsal striatum, mild brain injury significantly increased tonic glutamate levels by 200%. 
Tonic glutamate levels were significantly correlated with injury severity in the dentate 
gyrus and striatum. The amplitudes of KCl-evoked glutamate release were increased 
significantly only in the striatum after moderate injury, with a 249% increase seen in the 
dorsal striatum. Thus, with MEAs, we measured discrete regional changes in both tonic 
and KCl-evoked glutamate signaling, which were injury severity dependent. Future 
studies may reveal the specific mechanisms responsible for glutamate dysregulation in 
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the post-traumatic period, providing novel therapeutic targets to improve outcomes after 
TBI. 
 
Introduction 
Approximately 1.5 million Americans suffer from a traumatic brain injury (TBI) 
each year, with mild TBI accounting for as many as 75% of all the injuries (Centers for 
Disease Control and Prevention, 2003). Survivors of TBI often suffer from a wide variety 
of neurological deficits that impair quality of life (Baddeley 1992, Capruso and  Levin 
1992, McAllister 1992, Levine, et al. 2002). Glutamate signaling in the central nervous 
system (CNS) plays a pivotal role in the acute pathophysiology of TBI. Primary 
mechanical forces of the initial injury can compromise the blood-brain barrier and cellular 
membranes allowing increased glutamate release into the extracellular space (Schmidt 
and  Grady 1993, Bullock, et al. 1998, Farkas, et al. 2006). The redistribution of ions 
after injury can further depolarize neurons and augment the release of glutamate 
(Katayama, et al. 1990). Excessive glutamate receptor activation can promote cellular 
damage through secondary injury cascades by disrupting ionic homeostasis in the cell, 
activating calcium-dependent proteases and phospholipases, uncoupling mitochondrial 
ATP synthesis, promoting oxidative stress, producing reactive oxygen species, depleting 
glutathione levels, and increasing the energy demand of the cell (Faden, et al. 1989, 
Hall, et al. 1994, McIntosh, et al. 1996, Yi and  Hazell 2006). Further, clinical reports 
have reported increases in extracellular glutamate up to four days after injury that 
correlated with increased intracranial pressure and unfavorable outcomes (Bullock, et al. 
1995). These prior studies emphasize the consequences of CNS glutamate 
dysregulation, and the need to examine changes in glutamate signaling in the post-
traumatic period after TBI that may be responsible for aberrant neuronal signaling and 
the contribution to neurological deficits.  
Glutamate is released constantly into the extracellular space via stimulated and 
spontaneous exocytosis of synaptic vesicles and by carrier mediated exchange with 
other amino acids (Jabaudon, et al. 1999, Jensen, et al. 2000). Because there is no 
enzyme in the extracellular fluid to degrade glutamate, the synaptic concentration of 
glutamate is lowered by diffusion away from the synapse and through glutamate uptake. 
Since diffusion of glutamate is limited by the extrasynaptic anatomy, glutamate uptake is 
the primary mechanism to maintain the extracellular concentration of glutamate. In the 
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central nervous system, almost all of the glutamate clearance is achieved by the sodium-
dependent excitatory amino acid transporters (EAATs) GLAST and GLT-1, 
predominantly located on glia (Danbolt 2001). 
Previous studies have reported several fold increases in the extracellular 
concentration of glutamate initiated by a TBI, which subside within two hours (Faden, et 
al. 1989, Katayama, et al. 1990, Nilsson, et al. 1990, Matsushita, et al. 2000). These 
studies employed microdialysis, a common method for neurochemical sampling in vivo. 
However, microdialysis suffers from spatial and temporal limitations that restrict the 
ability to sample dynamic fluctuations of glutamate near the synapse (Obrenovitch, et al. 
2000, Hillered, et al. 2005). The large sampling area of the microdialysis membrane (1-4 
mm length) and extensive damage from implantation of the microdialysis probe limit the 
ability to detect neuronal release (Borland, et al. 2005, Jaquins-Gerstl and  Michael 
2009). Furthermore, the low temporal resolution of microdialysis (1-20 min) is 
inadequate to sample the fast dynamics of glutamate release and clearance that occurs 
on the order of milliseconds to seconds (Diamond 2005).  
Interestingly, experimental TBI has yet to produce pathological extracellular 
concentrations of glutamate, even immediately post-injury (Katayama, et al. 1990, 
Matsushita, et al. 2000), which raises doubt about glutamate excitotoxicity after TBI 
(Carbonell and  Grady 1999, Obrenovitch 1999). In this study, we used midline fluid 
percussion injury (FPI), a model of a diffuse closed head injury that affects both 
hemispheres equally and shares pathological features of human head injuries (Dixon, et 
al. 1987, McIntosh, et al. 1987), to examine changes in glutamate signaling two days 
after mild or moderate diffuse brain injury. To study injury-induced alterations in 
glutamate neurotransmission, we employed a novel technique, in vivo amperometry 
coupled to enzyme-based microelectrode arrays (MEAs), with high temporal resolution 
(2 Hz), low limit of detection (< 1 µM), and high spatial resolution to selectively measure 
extracellular glutamate closer to synapses (Burmeister and  Gerhardt 2001, Burmeister, 
et al. 2002). The improved spatial and temporal resolution of the MEAs allowed us to 
examine injury-induced alterations in tonic glutamate levels and potassium chloride 
(KCl)-evoked glutamate release in the prefrontal cortex, dentate gyrus of the 
hippocampus, and striatum; brain regions known to play a role in the behavioral, 
cognitive, and motor deficits suffered by TBI survivors (Baddeley 1992, Capruso and  
Levin 1992, McAllister 1992, Levine, et al. 2002). 
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Methods 
 
Animals 
Male Sprague-Dawley rats (350-400g; Harlan Laboratories Inc., Indianapolis, IN) 
were used for all experiments. The animals were housed in a 12 h light/dark cycle with 
food and water ad libitum according to the Association for Assessment and Accreditation 
of Laboratory Animal Care International. Animals were acclimated to their environment 
for at least 1 week before any experiments. After surgery, animals were monitored daily 
for post-operative care. Animal care was approved by the University of Kentucky 
Institutional Animal Care and Use Committee. 
 
Midline Fluid Percussion Injury 
Animals were subjected to midline FPI as previously described (Lifshitz 2008). 
Rats were anesthetized with isoflurane at 4% for five minutes and placed in a stereotaxic 
frame in a sterile surgery hood with continuously delivered isoflurane at 2%. The head 
was shaved and a 70% alcohol and betadine solution was applied. Eyes were treated 
with artificial tears and body temperature was maintained with a delta-phase heating pad 
(Braintree Scientific, Braintree, MA). A midline incision was made and fascia removed 
from the skull. A 4.7 mm trephine was used for the craniotomy, centered on the sagittal 
suture between bregma and lambda without disrupting the underlying dura or superior 
sagittal sinus. Anchoring screws were secured into pilot holes remote from the 
craniotomy. An injury hub was constructed from a Luer-Loc hub. The outer diameter of 
the hub was beveled to match the craniotomy. The injury hub was fitted into the 
craniotomy and cyanoacrylate gel was applied to seal the skull-hub interface. To secure 
the injury hub to the anchoring screws, methyl-methacrylate (Hygenic Corp., Akron, OH) 
was applied. The hub was filled with sterile saline and the wound sutured to prevent 
tearing. The animals were allowed to recover for 30-60 minutes until ambulatory and 
then re-anesthetized with 5% isoflurane for 5 minutes. The incision was opened and the 
injury hub was inspected. The female Luer-Loc injury hub was connected to the male 
Luer-Loc hub of the injury device (Custom Design and Fabrication, Virginia 
Commonwealth University, Richmond, VA). Before reflexive responses returned, the 
pendulum hammer was dropped onto the fluid-filled piston to induce either a mild or 
moderate injury. Sham injured animals underwent the same procedure without induction 
of injury. The fluid pressure pulse for mild injury was 1.1 ± 0.01 atm, and 2.0 ± 0.02 atm 
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for moderate injury. The injury hub was removed and any bleeding controlled with 
Gelfoam (Pharmacia, Kalamazoo, MI). The incision was closed with staples. Righting 
reflex recovery times were recorded for the injury group, from the time of impact to the 
time when animals’ spontaneously righted. Mild injured animals had righting reflex times 
of 144 ±34 seconds (n=10), and moderate injured animals had times of 606 ±85 seconds 
(n=11). Sham injured animals had righting reflex less than 15 seconds (n=10). No 
animals died from complications caused by the injury. 
 
Enzyme-Based Microelectrode Arrays 
Ceramic-based MEAs, consisting of four platinum recording sites (15 x 333 µm) 
arranged in dual pairs, were prepared and selected for in vivo recordings as previously 
described (Burmeister, et al. 2002, Day, et al. 2006). Glutamate-oxidase (GluOX) 
covered one pair of recording sites to allow for the enzymatic conversion of glutamate to 
α-ketoglutarate and the generation of the reporter molecule H2O2. An inactive protein 
matrix covered the other pair of recording sites (sentinel sites). The two different 
coatings allowed the use of a self-referencing technique, in which the background 
current of the sentinel sites can be subtracted from the current of the glutamate-oxidase 
sites, thereby producing a more selective glutamate measure (Burmeister and  Gerhardt 
2001, Burmeister, et al. 2002). A size exclusion layer of 1,3-phenylenediamine (mPD) 
restricted the passage of large molecules that can be oxidized, such as ascorbic acid 
(AA) and dopamine (DA). Small molecules, such as H2O2, diffuse through the exclusion 
layer, reaching the platinum recording sites (Fig 2.1A).  
A 10 µL solution of 1% bovine serum albumin (BSA) (Sigma-Aldrich, St. Louis, 
MO), 0.125% glutaraldehyde (Glut) (Sigma-Aldrich), and 1% glutamate-oxidase 
(Seikagaku America, East Falmouth, MA) was prepared. Using a dissecting microscope, 
a microsyringe was used to manually apply a small drop (~0.1µL) of the glutamate-
oxidase solution onto the bottom pair of platinum recording sites. Three enzyme coats 
were applied onto the platinum recording sites with a one minute drying period between 
each coat. The same procedure was used to coat the top pair of platinum recording sites 
(sentinel sites) with a solution containing 1% BSA and 0.125% glutaraldehyde. After 
coating, the MEAs were cured for at least 48 hours in a low humidity environment. The 
coated MEAs were connected to the FAST-16 mkII system (Fast Analytical Sensor 
Technology Mark II; Quanteon, L.L.C., Nicholasville, KY) and the tips of the MEAs were 
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placed in a 5 mM mPD solution (Acros Organics, Morris Plains, NJ). Electroplating 
software was used to apply a potential as a triangular wave with an offset of -0.5V, peak 
to peak amplitude equal to 0.25V, at a frequency of 0.05 Hz, for a period of 20 minutes 
to electroplate the mPD on all platinum recording sites. MEAs were cured for an 
additional 24 hours in a low humidity environment before use. 
 
MEA Calibration 
Calibrations were conducted to test the capability of the MEAs to measure 
glutamate and generate a standard curve for the conversion of current to glutamate 
concentration. Constant potential amperometry was performed with the MEAs using a 
FAST-16 mkII system. A potential of + 0.7 V versus a Ag/AgCl reference was applied to 
oxidize the reporter molecule, H2O2, which is a 2-electron oxidation reaction that occurs 
at the platinum recording sites of the MEA. The resulting current was amplified and 
digitized by the FAST-16 mkII system. The platinum recording sites of the MEA were 
placed in a continuously stirred 40 ml solution of 0.05 M phosphate buffered saline 
(PBS) maintained at 37 ºC with a re-circulating water bath (Gaymar Industries Inc., 
Orchard Park, NY). The MEAs were exposed to final concentrations of 250 µM AA, 20, 
40, 60 µM glutamate, 2 µM DA, and 8.8 µM H2O2 (Fig 2.1B). Parameters tested were 
limit of detection (LOD), selectivity for glutamate over ascorbic acid, slope of the 
electrode (sensitivity), and linearity of the glutamate response (R2). The average LOD 
was 0.8 ±0.1 µM, selectivity was 167 ±19:1 (glutamate: ascorbic acid), and slope was 
3.4 ±0.3 pA/µM (n=51 GluOX recording sites). 
In a separate study, we examined MEA performance after in vivo recordings. The 
post-implantation calibrations demonstrated that the parameters were not different (pre 
vs. post-implantation, n=24 glutamate-oxidase recording sites, paired t-test): limit of 
detection (1.1 ±0.1 µM vs. 1.5 ±0.4 µM, p=0.37), selectivity (93 ±21 vs. 83 ±26, p=0.77), 
and slope (2.1 ±0.2 pA/µM vs. 2.2 ±0.1 pA/µM, p=0.68). 
Oxygen is a required co-factor of glutamate-oxidase for the production of the 
reporter molecule, H2O2. Therefore, we examined if low oxygen concentrations would 
affect MEA performance. Glutamate responses were minimally affected by oxygen 
concentration and the performance even at 0 µM oxygen was within 80% of the MEA 
response obtained in air saturated buffer (200 µM). 
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MEA/Micropipette Assembly 
For local application of solutions in the rat brain, glass micropipettes (1 mm o.d. 
0.58 mm i.d., A-M Systems, Inc., Everett, WA) were pulled (Kopf Instruments, Tujunga, 
CA), and the tips of the micropipettes were bumped to create a tip with an i.d. of 10-15 
µm. The micropipettes were placed centrally among all four platinum recording sites and 
mounted 50-100 µm above the MEA. Micropipettes were filled with sterile filtered (0.20 
µm) isotonic KCl solution (70 mM KCl, 79 mM NaCl, 2.5 mM CaCl2 or 120 mM KCl, 29 
mM NaCl, 2.5 mM CaCl2, pH 7.4) concentrations previously used to elicit reproducible 
KCl-evoked glutamate release in the brain regions of interest (Burmeister et al., 2002; 
Day et al., 2006; Stephens et al., 2009). The micropipette was attached to a Picospritzer 
III (Parker-Hannifin, Cleveland, OH) with settings adjusted to consistently deliver 
volumes between 50-100 nl. Pressure was applied from 2-20 p.s.i. for 1 sec. Volume 
displacement was monitored with the use of a stereomicroscope fitted with a reticule 
(Friedemann and  Gerhardt 1992). 
 
In Vivo Anesthetized Recording 
Two days after midline FPI, rats were anesthetized with urethane (1.25 g/kg i.p.) 
(Sigma-Aldrich) and prepared for in vivo electrochemical recordings as previously 
described (Burmeister, et al. 2002, Pomerleau, et al. 2003, Day, et al. 2006). Briefly, 
animals were placed in a stereotaxic frame and body temperature was maintained at 37 
°C with a water pad connected to a recirculating water bath. A craniotomy was 
performed to provide access to the prefrontal cortex (AP: +3.2 mm, ML: +0.8 mm, DV:-
4.5 mm), dentate gyrus (AP: -4.3 mm, ML: +2.1 mm, DV -4.2), and striatum (AP: +1.0 
mm, ML: +2.5 mm, DV: -4.0, -4.5, -5.0 mm) (Paxinos and Watson, 1998) (Fig 2.1C). A 
Ag/AgCl reference wire was implanted into the lateral parietal cortex in the opposite 
hemisphere from the recording areas. The MEA was lowered into the brain using a 
microdrive (MO-10, Narishige International, East Meadow, NY). All MEA recordings were 
performed at a frequency of 2 Hz using constant potential amperometry. After the MEA 
reached a stable baseline (10-15 min), tonic glutamate levels (μM) were calculated by 
averaging extracellular glutamate levels over 10 seconds. Local application of KCl 
produced glutamate signals that were reproducible every 30 s. Each signal was 
analyzed by the following parameters: amplitude (μM), T80 (s) the time for the signal to 
decay by 80% from the peak amplitude, and k-1 (sec -1) the slope of the linear regression 
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of the natural log transformation of the decay over time (Fig 2.1D) (Thomas, et al. 2009). 
Approximately eight reproducible signals were evoked at each location and then 
averaged into a representative signal for comparisons between injury groups. After 
recording from all locations, a MEA with an attached micropipette was used to locally 
apply green waterproof drawing ink (Higgins, Ebhard Faber Inc., Lewisburg, TN), which 
was used to confirm MEA placement during brain sectioning.  
 
Data Analysis 
Amperometric data were analyzed using custom Microsoft Excel ™ - based 
software to determine the tonic levels and KCl-evoked signal parameters. To determine 
tonic levels of glutamate in the different brain regions, the background current from the 
sentinel site was subtracted from the current of the glutamate-oxidase site. Then, the 
resulting current (pA) was divided by the slope (µM/pA) obtained during the calibration to 
determine the tonic glutamate concentration in a given brain region. Data from the 
dentate gyrus and prefrontal cortex were analyzed by a one-way ANOVA followed by a 
Bonferonni post-hoc test. For the striatum, data were analyzed by a repeated measures 
two-way ANOVA followed by a Bonferonni post-hoc test (injury severity vs. depth). Data 
are presented as mean ±SEM. Statistical significance was defined as p < 0.05. 
 
Results 
 
Prefrontal Cortex: Tonic and Evoked Glutamate Release 
Tonic glutamate levels were not significantly changed in the prefrontal cortex two 
days after mild or moderate diffuse brain injury [ANOVA: F(2,18)=0.8, p=0.43] (Fig 2.2A). 
Tonic levels averaged 4.1 ±1.4 µM (sham), 4.2 ±1.3 µM (mild), and 6.2 ±2.5µM 
(moderate). Local application of ~50 nL of 120 mM KCl produced reproducible glutamate 
release in the prefrontal cortex. Representative recordings demonstrate similar evoked-
glutamate signals from local application of KCl between the sham and injury groups (Fig 
2.2B). The amplitudes of KCl-evoked glutamate release in the prefrontal cortex were not 
significantly changed after diffuse brain injury [ANOVA F(2,15)=0.49, p=0.62] (Fig 2.2C). 
The amplitudes of KCl-evoked glutamate release in the sham, mild and moderate brain-
injured rats were 5 to 10 times larger than the corresponding tonic levels of glutamate. 
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Amplitudes averaged 31.9 ±4.5 µM, 40.2 ±11.5 µM, and 27.8 ±9.6 µM in the sham, mild 
and moderate brain-injured groups, respectively. Clearance parameters (T80 and k-1) of 
the KCl-evoked glutamate signal back to tonic levels were equivalent between all groups 
(Table 2.1). Thus, mild or moderate midline FPI did not produce significant changes in 
the tonic glutamate concentration, the amplitude of KCl-evoked glutamate release, or 
glutamate clearance parameters in the prefrontal cortex. 
 
Dentate Gyrus: Tonic and Evoked Glutamate Release 
Tonic glutamate levels in the hippocampal dentate gyrus were significantly 
elevated after brain injury [ANOVA F(2,21)=4.9, p=0.018]. Tonic levels averaged 1.6 
±0.4 µM (sham), 4.3 ±1.4 µM (mild), and 5.7 ±2.3 µM (moderate). Moderate brain-injured 
animals exhibited a significant 256% increase in tonic glutamate levels compared to 
sham controls (Fig 2.3A). Tonic glutamate levels in mild brain-injured animals were not 
significantly different from either sham or moderate brain-injured animals. Local 
application of ~75 nL of 70 mM KCl produced reproducible glutamate release in the 
dentate gyrus. Representative recordings demonstrate similar evoked-glutamate signals 
from local application of KCl between the sham and brain injury groups (Fig 2.3B). 
Amplitudes of evoked-glutamate release in the dentate gyrus were not significantly 
different between groups [ANOVA F(2,18)=0.41, p=0.67] (Fig 2.3C). The amplitude of 
KCl-evoked glutamate release in the sham, mild and moderate injured rats were 4 to 15 
times larger than the tonic glutamate levels, as amplitudes averaged 25.1 ±4.9 µM, 19.1 
±4.9 µM, and 24.7 ±5.9 µM in the sham, mild and moderate brain-injured groups, 
respectively. Clearance parameters (T80 and k-1) of the KCl-evoked glutamate signal 
back to tonic levels were equivalent between all groups (Table 2.1).  Thus, tonic levels of 
extracellular glutamate were significantly increased after moderate midline FPI, with no 
significant changes in the amplitude of KCl-evoked glutamate release or glutamate 
clearance parameters in the dentate gyrus after mild or moderate midline FPI.  
 
Striatum: Tonic and Evoked Glutamate Release 
With the high spatial resolution of the platinum recording sites, glutamate 
responses were sampled from multiple depths of the large heterogeneous structure of 
the rat striatum (DV: -4.0 mm, -4.5 mm, -5.0 mm). Tonic glutamate levels were 
significantly affected by brain injury severity [F(2,42)=9.26, p=0.0005] and by recording 
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depth in the striatum [F(2,42)=4.87, p=0.0183]. At -4.0 mm in the striatum, tonic levels 
averaged 2.3 ±0.6 µM (sham), 6.9 ±1.2 µM (mild) and 6.4 ±1.2 µM (moderate). Mild and 
moderate brain injury produced a significant increase in tonic glutamate levels at a depth 
of -4.0 mm compared to sham control animals, with a significant 200% increase after 
mild brain injury and a significant 178% increase after moderate brain injury (Fig 2.4A). 
The injury-induced increases in tonic glutamate levels after mild and moderate brain 
injury compared to sham animals at recording depths of -4.5 mm and -5.0 mm did not 
reach significance. 
Local application of ~100 nL of 70 mM KCl produced reproducible glutamate 
release in all depths of the striatum. Representative recordings of KCl-evoked glutamate 
release in the dorsal striatum (-4.0 mm) demonstrate the significantly elevated amplitude 
of glutamate release after moderate brain injury (Fig 2.4B). At -4.0 mm in the striatum, 
the amplitude of KCl-evoked glutamate release were 10-25 times larger than the tonic 
glutamate concentration, as amplitudes averaged 14.9 ±2.4 µM, 16.1 ±1.9 µM and 52.0 
±16.6 µM in the sham, mild or moderate brain-injured animals, respectively. The 
amplitude of evoked-glutamate release was significantly affected by brain injury severity 
[F(2,42)=24.96, p<0.0001], but not by recording depth of the MEA [F(2,42)=0.02, 
p=0.97]. Amplitudes of KCl-evoked glutamate release after moderate brain injury were 
significantly elevated by 249%, 302%, 153% at -4.0, -4.5, and -5.0 mm, respectively (Fig 
2.4C). Clearance parameters (T80 and k-1) of the KCl-evoked glutamate signal back to 
tonic levels were equivalent in all depths of the striatum between all groups (Table 2.1). 
Thus, the striatum exhibits significantly elevated tonic glutamate levels after mild and 
moderate midline FPI, whereas the amplitude of KCl-evoked glutamate release was 
elevated significantly only after moderate brain injury. 
 
Tonic Glutamate Levels Correlate with Injury Force 
To examine if injury force (atm) is predictive of tonic glutamate levels, linear 
correlations were calculated for the three brain regions. The correlation was not 
significant in the prefrontal cortex (Pearson r2=0.05 p=0.30). However, tonic glutamate 
levels were significantly correlated with injury force in the dentate gyrus (Pearson 
r2=0.29; p=0.006) and in the striatum, when the three recording depths were averaged 
into a single value (Pearson r2=0.22; p=0.019) (Fig 2.5). Thus, injury force was predictive 
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of elevated tonic glutamate levels in the dentate gyrus and the striatum at two days after 
diffuse brain injury. 
Discussion 
We examined the extent of glutamate dysregulation two days after diffuse brain 
injury, which may contribute to aberrant neuronal signaling and the propagation of 
secondary injury cascades. The present study was a first attempt to use enzyme-based 
MEAs to examine regional changes in glutamate signaling after TBI. First, the prefrontal 
cortex exhibited no significant alterations in glutamate signaling two days after diffuse 
injury. Second, tonic glutamate levels in the dentate gyrus and striatum were significantly 
increased after midline FPI. Third, moderate midline FPI produced significant increases 
in the amplitudes of evoked-glutamate release in multiple depths of the striatum. Finally, 
tonic glutamate levels in the dentate gyrus and striatum were significantly correlated to 
the mechanical forces of injury.  
MEAs have improved upon some limitations inherent to microdialysis for 
sampling glutamate in vivo. The high spatial resolution of the platinum recording sites 
allowed glutamate measurements from discrete regions, which is vital in studying local 
glutamate regulation. Also, the 2 Hz sampling rate of the MEAs records the fast 
dynamics of glutamate signaling that may be susceptible to TBI pathophysiology. The 
improved spatial resolution and limited damage to the surrounding tissue (Rutherford, et 
al. 2007) allow MEAs to sample glutamate spillover from nearby synapses that are TTX 
sensitive (Day, et al. 2006, Hascup, et al. 2008). In contrast, microdialysate samples of 
glutamate are largely TTX independent and poorly correlated with the concentration of 
glutamate near synapses (Timmerman and  Westerink 1997, Obrenovitch 1999). 
Moreover, the small recording sites of the MEAs require little tissue oxygen utilization 
and the electrochemical oxidation of H2O2 produces oxygen as supplementary substrate 
for glutamate-oxidase. In anoxic tissue, such as stroke, MEA performance may be 
compromised. 
Tonic glutamate levels in the dentate gyrus and striatum are positively correlated 
with injury severity. However, the concentrations do not appear to reach excitotoxic 
levels, as a continuous infusion of 1.8 M glutamate at 0.5 µL/hr was insufficient to 
produce a neuropathological lesion (Mangano and  Schwarcz 1983). The present study 
was carried out under urethane anesthesia, which can decrease tonic glutamate levels 
by 60-80% (Rutherford, et al. 2007). Therefore, the values reported here may represent 
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only a fraction of the tonic glutamate concentration in the awake animal. Still, the 
increased tonic glutamate levels may contribute to the development or maintenance of 
diffuse brain injury pathophysiology. The observed tonic glutamate levels may explain 
elevated neuronal calcium levels, altered calcium regulation, which result in calpain 
mediated spectrin proteolysis reported after midline FPI (Sun, et al. 2008, McGinn, et al. 
2009). With regard to secondary injuries, increased tonic glutamate levels after the initial 
injury may produce increased susceptibility to excitotoxic damage or provide 
neuroprotection via preconditioning. Future work should examine the effect of increased 
tonic glutamate levels on a secondary insult and identify alternate sources of glutamate 
contributing to the increased tonic glutamate levels. 
Tonic glutamate levels seem independent of evoked-glutamate release as we 
report significant increases in tonic glutamate levels in the presence and absence of 
alterations in KCl-evoked glutamate release, depending on brain region. Evoked-
glutamate release, unlike the graded response in tonic glutamate levels, exhibited an all-
or-none response with injury severity. Local application of isotonic KCl depolarized local 
axons and pre-synaptic terminals, evoking neurotransmitter release. The increase in 
extracellular glutamate was transient as glutamate uptake rapidly restores the glutamate 
concentration back to tonic levels. Although transient, elevated evoked-glutamate 
release may prolong secondary injury cascades, by excessively activating ionotropic 
receptors, increasing calcium influx, and activating proteases (McIntosh, et al. 1996). 
Elevated evoked-glutamate release could arise from several different mechanisms. First, 
the pre-synaptic terminal could release more glutamate vesicles or vesicles with higher 
glutamate concentrations. Lateral FPI produces transient changes in the synaptic 
machinery, specifically complexin I and II, up to one week after injury, which could alter 
neurotransmitter packaging and synaptic release (Yi and  Hazell 2006). Furthermore, 
free radicals can increase KCl-evoked glutamate release (Pellegrini-Giampietro, et al. 
1990). Second, reduced glutamate transporter function would increase the extracellular 
glutamate concentration. Controlled cortical impact decreases the expression of GLT-1 
and GLAST, the EAATs which mediate most of the glutamate uptake in the rat brain 
(Rothstein, et al. 1996, Rao, et al. 1998). Third, synaptic reorganization may alter 
synaptic structure and function. Future work could explore clearance of locally applied 
glutamate into the extracellular space to evaluate EAATs surface expression (Nickell, et 
al. 2007).  
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Midline FPI produces a diffuse, multi-focal pathology with significant neurological 
impairments after mild and moderate injury, without overt cavitation (McIntosh, et al. 
1987, Schmidt and  Grady 1993, Hamm 2001, Kelley, et al. 2007). In addition, 
physiological disturbance may contribute to observed post-traumatic deficits (Lyeth, et 
al. 1990, Delahunty, et al. 1995). The spectrum of deficits includes behavioral, cognitive 
and motor impairments ascribed to the prefrontal cortex, hippocampus, and striatum 
(Baddeley 1992, Capruso and  Levin 1992, McAllister 1992, Levine, et al. 2002, Khan, et 
al. 2003). 
The medial prefrontal cortex receives glutamatergic projections from the 
mediodorsal nucleus of the thalamus, hippocampus, and amygdala (Steketee 2003). 
Post-traumatic impairments in working memory have been linked to damage in the 
medial prefrontal cortex (Baddeley 1992, Delatour and  Gisquet-Verrier 2000, Levine, et 
al. 2002). Here, we report no significant changes in tonic glutamate levels or evoked 
glutamate release in the medial prefrontal cortex, likely due to the injury type or the 
selected time point. Few reports have examined the prefrontal cortex after midline FPI, 
reporting blood-brain barrier disruption within 24 hours post-injury (McIntosh, et al. 1987, 
Schmidt and  Grady 1993). After controlled cortical impact, impairments in working 
memory have been attributed to excessive GABA-meditated inhibition weeks post-injury 
(Kobori, et al. 2006, Kobori and  Dash 2006). Thus, diffuse brain injury in the medial 
prefrontal cortex retains glutamate regulation at two days post-injury. 
The dentate gyrus of the hippocampus receives glutamate projections from the 
entorhinal cortex and projects to area CA3 (Andersen 2007). Survivors of TBI suffer from 
impairments in learning and memory attributed to hippocampal damage (Tate and  Bigler 
2000). Midline FPI produces significant deficits in the Morris water maze memory tests 
11-15 days after injury (Hamm, et al. 1993, Liu, et al. 1994). In the absence of significant 
neuronal cell death, physiological changes in the hippocampus may contribute to the 
functional deficits (Lyeth, et al. 1990, Delahunty, et al. 1995, Grady, et al. 2003). The 
significantly elevated tonic glutamate levels after moderate brain injury may provide a 
potential substrate for the increased hippocampal excitability reported two days after 
midline FPI (Reeves, et al. 1995) and ensuing cognitive deficits.  
The striatum receives glutamatergic projections from the thalamus and virtually 
all regions of the neocortex (Fonnum, et al. 1981). Survivors of TBI suffer motor and 
cognitive impairments (Khan, et al. 2003), as reported with glutamate and dopamine 
dysregulation in the striatum (Canales, et al. 2002). Injury-induced increases in tonic and 
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evoked-glutamate release in the striatum at two days post-injury may underlie the motor 
deficits within five days post-injury and the memory deficits within 11-15 days post-injury 
(Liu, et al. 1994, Hamm 2001). Two weeks after controlled cortical impact, dopamine 
neurotransmission in the striatum exhibited decreased electrically-induced dopamine 
overflow, decreased levels of the dopamine transporter, and decreased dopamine 
uptake from the extracellular space (Wagner, et al. 2005). Activation of ionotropic 
glutamate receptors reduces evoked-dopamine release in the striatum (Wu, et al. 2000). 
The glutamate-dopamine interactions underlying motor and cognitive function warrant 
further investigation to explain the neurological deficits observed in experimental and 
clinical TBI. 
In conclusion, we used MEAs in combination with midline FPI to examine how 
diffuse brain injury alters glutamate signaling without the influence of tissue destruction 
seen in focal injury models. Our results demonstrate that elevated glutamate signaling 
contributes to the pathophysiology of diffuse brain injury, establishing a basis for further 
functional deficits. The specific mechanisms responsible for the elevations in tonic 
glutamate levels and evoked-glutamate release in vivo should be explored over a more 
complete time course to identify novel therapeutic targets to improve outcomes after TBI. 
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Chapter Two: Figures 
 
Figure 2.1 Methods for microelectrode array glutamate recordings 
 
(A) Schematic diagram showing the configuration and coatings applied to the MEA. The 
lower pair of platinum sites were prepared with a mixture of glutamate-oxidase (GluOX), 
bovine serum albumin (BSA), and glutaraldehyde (Glut), illustrated at left. While the 
upper pair of platinum sites were prepared only with BSA and Glut, illustrated at right. A 
layer of m-phenylenediamine (mPD) is electroplated onto the recording sites providing a 
size exclusion layer to block major interferents, ascorbic acid (AA) and dopamine (DA). 
(B) MEA in vitro calibration measuring the change in current on a GluOX site (solid line) 
and a sentinel site (dashed line) with addition of multiple analytes (↑). Additions of 
interferents such as AA and DA produced no change in current on the GluOX or sentinel 
sites. Three glutamate (Glu) additions showed a stepwise increase of current on the 
GluOX site with no response on the sentinel site. Addition of H2O2 produces an increase 
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in current on both the GluOX and sentinel sites. (C) Illustrations of coronal sections of 
the rat brain (Paxinos and Watson, 1998) highlight the regions of interest for glutamate 
recordings (*)in the prefrontal cortex (PFC, AP: 3.2 mm), striatum (STR, AP: 1.0 mm), 
and dentate gyrus (DG, AP: -4.3 mm). (D) Representative in vivo recording from a 
GluOX site and sentinel site. Local application of KCl (↑) produced reproducible 
glutamate release, highlighting the fast kinetics of glutamate release and uptake. Tonic 
glutamate was calculated in each brain region after the microelectrode had reached a 
stable baseline. KCl-evoked glutamate release was analyzed using the following 
parameters: amplitude, T80, and k-1 for each signal. Parameters are shown separately for 
clarity.  
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Figure 2.2 Tonic and KCl-evoked release of glutamate in the prefrontal cortex of 
the urethane anesthetized rat 
 
(A) Tonic glutamate levels were not significantly different after mild or moderate midline 
FPI (n= 7). (B) Baseline-matched representative recordings exhibit no significant change 
in KCl-evoked glutamate release after midline FPI. Local application of KCl (↑) produced 
a robust increase in extracellular glutamate that rapidly returned to tonic levels. (C) The 
average amplitudes of KCl-evoked glutamate release were not significantly different after 
mild or moderate midline FPI (n= 6). 
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Figure 2.3 Tonic and KCl-evoked release of glutamate in the dentate gyrus in the 
hippocampus of the urethane anesthetized rat 
 
(A) Tonic glutamate levels were significantly increased after moderate midline FPI in the 
dentate gyrus (* p< 0.05, n= 8). (B) Baseline-matched representative recordings exhibit 
no significant change in KCl-evoked glutamate release after midline FPI. (C) The 
average amplitudes of KCl-evoked glutamate release were not significantly different after 
mild or moderate injury (n= 7). 
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Figure 2.4 Tonic and KCl-evoked release of glutamate in the striatum of the 
urethane anesthetized rat 
 
(A) Tonic glutamate levels were significantly increased after mild or moderate injury in 
the striatum at a depth of -4.0 mm with no significant changes at -4.5 mm or -5.0 mm (* 
p< 0.05, n= 8). (B) Baseline-matched representative recordings of KCl-evoked glutamate 
release showed that there was a significant increase in the amplitude of glutamate 
release after moderate midline FPI. Local application of KCl (↑) produced a robust 
increase in extracellular glutamate that rapidly returned to tonic levels. (C) The average 
amplitudes of KCl-evoked glutamate release in the rat striatum at -4.0 mm, -4.5 mm, -5.0 
mm were significantly increased after moderate midline FPI from local application of 100 
nL of 70 mM KCl, compared to sham or mild injury animals (* p< 0.05, ** p< 0.01, n= 8). 
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Figure 2.5 Correlations of tonic glutamate levels with force of injury in the rat 
prefrontal cortex, dentate gyrus, and striatum 
 
Tonic glutamate levels were not significantly correlated with injury force in the prefrontal 
cortex (n= 7), but were significantly correlated in the dentate gyrus (** p < 0.01, n= 8), 
and in the striatum (* p < 0.05, n= 8). 
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Chapter Two: Tables 
 
Table 2.1 Clearance Parameters of KCl-Evoked Glutamate Release  
 
 
  T 80 (sec)   k -1 (sec-1)  
 Sham Mild Moderate Sham Mild Moderate 
Prefrontal Cortex 7.0 ±0.6 8.7 ±1.5 7.4 ±1.6 0.11 ±0.02 0.11 ±0.02 0.15 ±0.01 
Dentate Gyrus 5.5 ±0.8 7.1 ±1.3 5.6 ±0.6 0.17 ±0.03 0.17 ±0.03 0.16 ±0.05 
Striatum (-4.0 mm) 5.4 ±0.4 6.0 ±0.6 6.9 ±0.8 0.14 ±0.02 0.14 ±0.03 0.13 ±0.02 
Striatum (-4.5 mm) 4.3 ±0.3 5.3 ±1.2 5.1 ±0.8 0.21 ±0.04 0.19 ±0.05 0.25 ±0.02 
Striatum (-5.0 mm) 4.4 ±0.6 5.9 ±1.5 5.9 ±1.1 0.27 ±0.06 0.18 ±0.04 0.21 ±0.03 
Mean ±SEM; Prefrontal Cortex n= 6; Dentate Gyrus n= 7; Striatum n= 8 
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Preface to Chapter Three  
 
The aim of the experiments in Chapter Three was to examine how neurons and 
glia regulate extracellular glutamate to determine the source of increased extracellular 
glutamate after diffuse traumatic brain injury. Using glutamate-sensitive microelectrode 
arrays (MEAs) coupled with targeted pharmacological agents, I developed a model on 
the regulation of extracellular glutamate by neurons and glia.  Furthermore, I detected 
disruptions in the release and regulation of extracellular glutamate by both neurons and 
glia after diffuse brain injury. Overall, this study uncovers specific targets to try to 
improve the regulation of extracellular glutamate with therapeutics after TBI. 
 
Chapter Three: Disruptions in the Regulation of Extracellular Glutamate by 
Neurons and Glia in the Rat Striatum Two Days after Diffuse Brain Injury 
 
Abstract 
Disrupted regulation of extracellular glutamate in the central nervous system 
contributes to and can exacerbate the acute pathophysiology of traumatic brain injury 
(TBI). Previously, we reported increased extracellular glutamate in the striatum of 
anesthetized rats at two days after diffuse brain injury. To determine the mechanism(s) 
responsible for increased extracellular glutamate, we used enzyme-based 
microelectrode arrays (MEAs) coupled with specific pharmacological agents targeted at 
in vivo neuronal and glial regulation of glutamate. After TBI, extracellular glutamate was 
significantly increased in the striatum by ~90% averaging 4.1 ±0.6 µM compared to 
sham 2.2 ±0.4 µM. Calcium-dependent neuronal glutamate release, investigated by local 
application of a N-type calcium channel blocker, was no longer a significant source of 
extracellular glutamate after TBI compared to sham. In brain-injured animals, inhibition 
of glutamate uptake with local application of an excitatory amino acid transporter 
inhibitor produced significantly greater increase in glutamate spillover (~65%) from the 
synapses of brain-injured animals compared to sham. Furthermore, glutamate clearance 
measured by locally applying glutamate into the extracellular space revealed significant 
reductions in the glutamate clearance parameters in brain-injured animals compared to 
sham. Taken together, these data indicate disruptions in calcium-mediated glutamate 
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release and glial regulation of extracellular glutamate contribute to increased 
extracellular glutamate in the striatum two days after diffuse brain injury. Overall, these 
data suggest that therapeutic strategies used to regulate glutamate release and uptake 
may improve excitatory circuit function and possibly outcomes following TBI. 
 
Introduction 
The central nervous system requires strict regulation of extracellular glutamate to 
guard against aberrant neuronal signaling and possible excitotoxicity. Disrupted 
glutamate regulation plays a pivotal role in the acute pathophysiology of traumatic brain 
injury (TBI) through the initiation of secondary injury cascades (McIntosh, et al. 1996, 
Bullock, et al. 1998). The primary physical and mechanical forces of a TBI disrupt the 
blood-brain barrier and cellular membranes leading to a release of intracellular contents 
into the extracellular space (Schmidt and  Grady 1993, Bullock, et al. 1998). 
Furthermore, disruptions in ionic regulation after TBI create a massive depolarization or 
wave of depolarizations that promotes excessive neuronal glutamate release 
(Katayama, et al. 1990). Moreover, post-traumatic reductions in the expression of 
excitatory amino acid transporters (EAATs) responsible for removing glutamate from the 
extracellular space leads to further increases in extracellular glutamate levels (Rao, et al. 
1998, van Landeghem, et al. 2001, Yi, et al. 2005, van Landeghem, et al. 2006, Yi and  
Hazell 2006). High extracellular glutamate propagates secondary injury cascades 
through the activation of glutamate receptors, increasing ionic flux, disrupting ionic 
homeostasis, activating calcium-dependent proteases and phospholipases, uncoupling 
ATP synthesis, and producing reactive oxygen species (Faden, et al. 1989, Hall, et al. 
1994, McIntosh, et al. 1996, Yi and  Hazell 2006).                                        
Glutamate is normally released into the extracellular space by both neuronal and 
non-neuronal sources (Jabaudon, et al. 1999, Jensen, et al. 2000). Once in the 
extracellular space, glutamate binds to both ionotropic glutamate receptors and 
metabotropic glutamate receptors (mGluRs) for signal propagation. For removal of 
glutamate from the extracellular space, five high affinity sodium-dependent excitatory 
amino acid transporters (EAATs), GLAST, GLT-1, EAAC, EAAT4, and EAAT5, are 
expressed throughout the central nervous system (Danbolt 2001). Glutamate uptake is 
driven by electrochemical gradients across neurons and glia with the majority (~90%) of 
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glutamate uptake performed by two glial transporters in the rat striatum, GLAST and 
GLT-1 (Rothstein, et al. 1996, Tanaka, et al. 1997, Danbolt 2001). 
Clinically, a multitude of studies have detected significant increases in 
extracellular glutamate levels in the days following injury with some reports correlating 
increases in extracellular glutamate with unfavorable  outcomes (Persson and  Hillered 
1992, Bullock, et al. 1995, Bullock, et al. 1998, Koura, et al. 1998, Vespa, et al. 1998, 
Yamamoto, et al. 1999, Reinert, et al. 2000, Hutchinson, et al. 2002, Hlatky, et al. 2004, 
Chamoun, et al. 2010, Lakshmanan, et al. 2010, Timofeev, et al. 2011a). These studies 
emphasize the significance of glutamate dysregulation in the acute pathophysiology and 
consequences of TBI. Unlike the clinical studies, multiple animals studies report 
increases in extracellular glutamate at the time of the injury, which returns to baseline 
concentrations within a few hours (Faden, et al. 1989, Katayama, et al. 1990, Nilsson, et 
al. 1990, Palmer, et al. 1993, Globus, et al. 1995, Katoh, et al. 1997, Stoffel, et al. 1997, 
Matsushita, et al. 2000, Rose, et al. 2002, Stoffel, et al. 2002). Because experimental 
TBI has failed to model glutamate dysregulation seen in the clinic, the role of glutamate 
excitotoxicity in the acute pathophysiology of TBI has been challenged and remains 
unclear (Carbonell and  Grady 1999, Obrenovitch 1999).  
Using novel enzyme-based microelectrode arrays (MEAs) to measure 
extracellular glutamate, we previously reported significant increases in extracellular 
glutamate and evoked glutamate release in the striatum two days after midline fluid 
percussion brain injury (Hinzman, et al. 2010). The purpose of this study was to examine 
the regulation of extracellular glutamate by both neurons and glia to identify specific 
mechanism(s) responsible for the increased extracellular glutamate in the rat striatum 
two days after diffuse brain injury. Using targeted pharmacological agents, we examined 
how both neurons and glia release and regulate extracellular glutamate. First, we 
examined the contribution of calcium-mediated neuronal glutamate release to 
extracellular glutamate by locally applying an N-type calcium channel blocker (ω-
conotoxin). Second, we examined if transient activation of the group II mGluRs 
(mGluR2/3) would improve neuronal regulation of extracellular glutamate by locally 
applying a mGluR2/3 agonist (LY 379268). Third, we examined non-neuronal sources of 
extracellular glutamate such as the glial expressed cystine/glutamate exchanger (xc-) by 
locally applying a xc- blocker ((S)-4-carboxyphenylglycine: CPG). Fourth, we examined 
how glia regulate extracellular glutamate by inhibiting glutamate uptake with a 
competitive non-transportable EAATs blocker (D,L-threo-β-benzyloxyaspartate: TBOA). 
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Finally, we directly tested the ability of glia to clear glutamate from the extracellular 
space. 
 
Materials and Methods 
 
Animals 
Male Sprague-Dawley rats (300-400g; Harlan Laboratories Inc., Indianapolis, IN) 
were used for all experiments (n =45). The animals were housed in a 12 h light/dark 
cycle with food and water available ad libitum according to the Association for 
Assessment and Accreditation of Laboratory Animal Care International. Animals were 
acclimated to their environment for at least one week before any experiments. After 
surgery, animals were evaluated daily for post-operative care by a physical examination 
of the rat screening the animals breathing, gait, coat appearance, dehydration, body 
appearance, locomotion, and food and water intake. Animal care was approved by the 
University of Kentucky Institutional Animal Care and Use Committee. 
 
Midline fluid percussion injury (FPI) 
Animals were subjected to midline FPI as previously described (Lifshitz 2008, 
Hinzman, et al. 2010, Thomas, et al. 2011). Rats were initially anesthetized with 
isoflurane at 5% for five minutes and placed in a stereotaxic frame in a sterile surgery 
hood with continuously delivered isoflurane at 2%. The head was shaved and a 70% 
alcohol and betadine solution was applied to the skin. Eyes were treated with artificial 
tears and body temperature was maintained with a delta-phase heating pad at ~37oC 
(Braintree Scientific, Braintree, MA). A midline incision was made and fascia removed 
from the skull. A 4.7 mm trephine was used for the craniotomy, centered on the sagittal 
suture between bregma and lambda without disrupting the underlying dura or superior 
sagittal sinus. Anchoring screws were secured into pilot holes remote from the 
craniotomy. An injury hub was constructed from a Luer-Loc hub (20 gauge needle). The 
outer diameter of the hub was beveled to match the craniotomy. The injury hub was 
fitted into the craniotomy and cyanoacrylate gel was applied to seal the skull-hub 
interface. To secure the injury hub to the anchoring screws, methyl-methacrylate 
(Hygenic Corp., Akron, OH) was applied. The hub was filled with sterile saline and the 
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wound sutured to prevent tearing. The female Luer-Loc injury hub was connected to the 
male Luer-Loc hub of the injury device (Custom Design and Fabrication, Virginia 
Commonwealth University, Richmond, VA). Before reflexive responses returned, the 
pendulum hammer of the injury device was dropped onto the fluid-filled piston to induce 
a moderate injury. Sham injured animals underwent the same procedure without 
induction of injury. The fluid pressure pulse for the brain injury was 2.0 ± 0.01 atm. The 
injury hub was removed and any bleeding controlled with Gelfoam (Pharmacia, 
Kalamazoo, MI). The incision was closed with staples. Righting reflex recovery times 
were recorded for the injury group, from the time of impact to the time when animals’ 
spontaneously righted. Brain injured animals had righting times of 437 ±19 seconds (n 
=23). Sham injured animals had righting reflex less than 15 seconds (n =22). No animals 
died from complications caused by the injury. 
 
Enzyme-based microelectrode arrays 
Ceramic-based MEAs, consisting of four platinum recording sites (15 x 333 µm) 
arranged vertically in dual pairs, were prepared and selected for in vivo recordings as 
previously described (Burmeister, et al. 2002, Day, et al. 2006, Hascup, et al. 2007, 
Stephens, et al. 2009, Hinzman, et al. 2010). Briefly, a glutamate-oxidase solution 
covered one pair of recording sites to allow for the enzymatic conversion of glutamate to 
α-ketoglutarate and the generation of the reporter molecule, H2O2. The small amount of 
H2O2 generated by glutamate-oxidase on the surface of the MEA will have a minimal 
impact on the production of reactive oxygen species in the local area due to the small 
amount of glutamate-oxidase coated on the surface of the MEA, the oxidation of H2O2 by 
the MEA, and the limited time of the MEA in the tissue. An inactive protein matrix 
covered the other pair of recording sites (sentinel sites). The two different coatings 
allowed the use of a self-referencing technique, in which the background current of the 
sentinel sites could be subtracted from the current of the glutamate-oxidase sites, 
thereby producing a more selective glutamate measure allowing the determination of 
tonic levels of glutamate (Burmeister and  Gerhardt 2001, Burmeister, et al. 2002). 
Furthermore, a size exclusion layer of 1,3–phenylenediamine (mPD) was electroplated 
onto the platinum recording sites to restrict the passage of large molecule interferents 
(ascorbic acid and dopamine) from reaching the platinum recording sites to further 
improve the selectivity of the MEA’s for glutamate detection (Hinzman, et al. 2010).  
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MEA calibration 
Constant potential amperometry was performed with the MEAs using the FAST-
16 mkII system (Quanteon Inc., LLC, Nicholasville, KY). A potential of +0.7 V versus an 
Ag/AgCl reference was applied to oxidize the reporter molecule, H2O2. The resulting 
current was amplified and digitized by the FAST-16 mkII system. Calibrations were 
conducted to test the capability of the MEA to selectively measure glutamate and to 
generate a standard curve for the conversion of current to concentration of glutamate. 
The parameters tested were limit of detection (three times the standard deviation of the 
baseline noise), selectivity (ability of the MEA to measure glutamate compared to a 
major interferent, ascorbic acid), and slope of the electrode (the linear increase in 
current due to additions of glutamate). The average limit of detection was 0.99 ±0.1 µM, 
selectivity was 301 ±57 (glutamate: ascorbic acid), and slope was 8.7 ±0.6 pA/µM 
(n=113 glutamate recording sites).  Calibrations were conducted before in vivo 
experimentation to ensure MEAs were functional before implantation and prior results 
have shown similar performance of the MEAs between pre- and post-experimental 
testing (Hinzman, et al. 2010).  
 
MEA/micropipette assembly 
For local application of solutions into the rat brain, glass micropipettes (1 mm o.d. 
0.58 mm i.d., A-M Systems, Inc., Everett, WA) were pulled (Kopf Instruments, Tujunga, 
CA), and the tips of the micropipettes were bumped to create a tip with an i.d. of 10-15 
µm. The micropipettes were placed centrally among all four platinum recording sites and 
mounted 50-100 µm above the MEA. Micropipettes were filled with (1) 10 µM ω-
conotoxin GVIA, N-type calcium channel blocker, (Alomone Labs, Jerusalem, Israel); (2) 
100 µM LY 379268, mGluR 2/3 receptor agonist, (Tocris, Ellisville, MO); (3) 50 µM (S)-4-
carboxyphenylglycine (CPG), xc- blocker, (Tocris, Ellisville, MO); (4) 100 µM  D,L-threo-β-
benzyloxyaspartate (TBOA), EAATs competitive inhibitor, (Tocris, Ellisville, MO); (5)  
500 µM glutamate (Sigma-Aldrich, St. Louis, MO); or (6) physiological saline (Day, et al. 
2006, Hascup, et al. 2010). All drugs were dissolved to their final concentrations in 
physiological saline. Solutions were sterile filtered (0.20 µm) and adjusted to a pH of 7.4. 
The micropipette was connected to a Picospritzer III (Parker-Hannifin, Cleveland, OH) 
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with settings adjusted to consistently deliver volumes between 12.5-350 nL. Pressure 
was applied from 2-30 psi for 0.3-3 sec. Volume displacement was monitored with the 
use of a stereomicroscope fitted with a reticule to determine and control the volume of 
solution that was locally applied by pressure ejection. (Friedemann and  Gerhardt 1992).  
 
In vivo anesthetized recordings of extracellular glutamate 
Two days after midline FPI, rats were anesthetized with urethane (1.25 g/kg i.p.) 
(Sigma-Aldrich) and prepared for in vivo electrochemical recordings as previously 
described (Day, et al. 2006, Hascup, et al. 2007, Stephens, et al. 2009, Thomas, et al. 
2009, Hinzman, et al. 2010, Thomas, et al. 2011). Briefly, animals were placed in a 
stereotaxic frame and body temperature was maintained at ~37 °C with a water pad 
connected to a recirculating water bath. A craniotomy was performed to provide access 
to the striatum (AP: +1.0 mm, ML: +/- 2.5 mm, DV: -3.5, -4.0, -4.5, -5.0 mm), (Paxinos 
and Watson, 1998). A Ag/AgCl reference wire was implanted into the lateral parietal 
cortex. The MEA was lowered into the brain using a microdrive (MO-10, Narishige 
International, East Meadow, NY). All MEA recordings were performed at a frequency of 
2 Hz.  
To measure tonic extracellular glutamate, the background current from the 
sentinel site was subtracted from the current of the enzyme site. Then, the resulting 
current (pA) was converted to glutamate concentration by dividing the current by the 
slope (pA/µM) obtained during the calibration. To examine the effect of drugs on 
extracellular glutamate, 100 nL of physiological saline was locally applied to assess 
potential dilution effects. Then, the solution in the micropipette was exchanged and 100 
nL of the drug of interest was locally applied into the striatum using the same application 
parameters. The maximum increase/decrease in extracellular glutamate and area 
above/below the curve (to examine the extent of changes in extracellular glutamate with 
respect to time) were calculated for both local application of saline and the drugs of 
interest. To examine glutamate clearance, varying volumes of 500 µM glutamate were 
applied into the extracellular space. Glutamate signals with amplitudes in the 5-50 μM 
range were analyzed as this was the physiological range of KCl-evoked glutamate 
release seen in sham and brain injured rats (Hinzman, et al. 2010). Glutamate clearance 
was analyzed for the following parameters: (1) amplitude (μM); (2) Trise (s), the time for 
the signal to reach the peak amplitude; (3) T80 (s), the time for the signal to decay by 
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80% from the peak amplitude; (4) and k-1 (sec -1), the slope of the linear regression of the 
natural log transformation of the decay over time (Nickell, et al. 2007, Thomas, et al. 
2009, Hinzman, et al. 2010).  
 
Quantitative gene expression (rtPCR) 
Two days post-injury, sham and brain-injured animals were transcardially 
perfused with cold saline, the brains rapidly removed from the skull, dissected into 2 mm 
slices using a chilled rat brain matrix, and a 1 mm diameter biopsy was removed from 
the dorsal striatum. The mRNA content was stabilized (RNAlater, Qiagen Corp) and 
stored frozen. Isolated mRNA (RNeasy, Qiagen Corp) was quantified (NanoDrop ND-
1000 spectrophotometer), converted to complementary DNA (cDNA; High Capacity 
cDNA Archive Kit, Applied Biosystems Inc.) and then used as a template for selected 
commercially-available gene expression assays for quantitative real-time PCR 
(StepONE, Applied Biosystems). The Applied Biosystems TaqMan® Gene Expression 
Assays (GLT-1: Rn00568080_m1; GLAST: Rn00570130_m1; 18s rRNA: 4352930E) 
were used for EAAT gene expression. Within each animal, relative gene expression was 
normalized to the 18s rRNA endogenous control and the expression level in the 
sham/vehicle group using the 2-ΔΔCT method (Livak and  Schmittgen 2001), which relates 
gene expression to the PCR cycle number at which the fluorescence signals exceed a 
threshold above baseline. Relative gene expression was compared between sham and 
brain-injured animals using a two-tailed t-test.  
Statistical analyses 
Amperometric data were analyzed using custom MATLAB® - based software. For 
both resting extracellular glutamate and analysis of glutamate clearance, multiple depths 
in the striatum were averaged per animal as there were no sub-regional differences 
detected. All data were analyzed using a two-tailed t-test. Data are presented as mean ± 
SEM, and statistical significance was defined as p < 0.05. 
 
Results 
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Increased extracellular glutamate in the striatum of brain-injured rats 
Previously, our laboratory has reported increased extracellular glutamate in the 
striatum two days after midline fluid percussion injury (Hinzman, et al. 2010). Here, we 
confirm the original finding detecting significantly higher extracellular glutamate after TBI 
than in sham [t30 = 2.681, p = 0.012] (Fig 3.1). Extracellular glutamate averaged 2.2 ± 0.4 
µM (Sham) vs. 4.1 ± 0.6 µM (TBI). Since we detected significant increases in 
extracellular glutamate after TBI, we set out to pharmacologically manipulate the 
regulation of glutamate by both neurons and glia to determine the possible 
mechanism(s) responsible for the increased extracellular glutamate after TBI.  
 
Reduced calcium channel-dependent glutamate release in the striatum of 
brain-injured rats 
By applying a N-type calcium channel blocker (ω-conotoxin) into the extracellular 
space, we examined the contribution of calcium-mediated vesicular glutamate release 
on extracellular glutamate. In sham, local application of ω-conotoxin produced a 
significant (~80 %) decrease in extracellular glutamate and reduced glutamate for a 
longer period of time (area under curve) compared to local application of saline (Table 
3.1). After TBI, local application of ω-conotoxin failed to reduce the extracellular 
glutamate concentration compared to local application of saline (Table 3.1). Averaged 
group responses to the local application of ω-conotoxin into the striatum in both sham 
and TBI groups demonstrate the reduced efficacy of ω-conotoxin on reducing 
extracellular glutamate after TBI (Fig 3.2A). The maximum decrease in extracellular 
glutamate in the presence of ω-conotoxin was significantly smaller after TBI compared to 
sham [t6 = 2.901, p = 0.028] (Fig 3.2B). Also, the extent of reduced glutamate with 
respect to time (area under curve) was significantly reduced after TBI as compared to 
sham [t6 = 3.113, p = 0.021] (Fig 3.2C). Thus, in sham animals calcium-mediated 
neuronal glutamate release was a significant source to extracellular glutamate. 
Whereas, calcium-mediated neuronal glutamate release was no longer a significant 
source to extracellular glutamate in brain-injured animals. Consequently, increased 
calcium-dependent glutamate release is unlikely to be a predominant mechanism for 
increased extracellular glutamate after TBI.   
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Activation of mGluR2/3 failed to reduce extracellular glutamate in the 
striatum of sham and brain-injured rats 
Additional studies were carried out to investigate other potential presynaptic 
changes in glutamate regulation after TBI. By applying an mGluR2/3 agonist (LY 379268) 
into the extracellular space, we examined if transient activation of the glutamate 
autoreceptors, mGluR2/3, would reduce neuronal glutamate release and thereby improve 
regulation of extracellular glutamate. Local application of LY 379268 failed to produce a 
significant decrease in extracellular glutamate compared to local application of saline in 
sham and after TBI (data not shown). Thus, insufficient mGluR2/3 activation is unlikely to 
be responsible for increased extracellular glutamate after TBI. 
 
Inhibition of the glial xc- failed to reduce extracellular glutamate in the 
striatum of sham and brain-injured rats 
Another glial source of extracellular glutamate may be derived from the xc-, 
predominantly localized to glia. Considerable attention has recently been paid to the xc- 
and its possible role in glutamate dysregulation by glia in drug abuse (Kalivas 2009). By 
applying a xc- blocker (CPG) into the extracellular space, we examined the contribution 
of glutamate release through the xc- on extracellular glutamate. Local application of CPG 
failed to produce a significant decrease in glutamate compared to local application of 
saline in sham and after TBI (data not shown). Thus, glial glutamate release through the 
xc- is not a significant source of extracellular glutamate in sham and TBI animals, and 
glutamate release through the xc- unlikely to be a mechanism for increased extracellular 
glutamate after TBI. 
 
Increased glutamate spillover from the inhibition of glutamate uptake in the 
striatum of brain-injured rats 
We further examined if disruptions in the regulation of extracellular glutamate by 
glia were responsible for the increased extracellular glutamate after TBI. Glutamate 
uptake through the EAATs, predominantly localized to glia, is the primary mechanism for 
regulating extracellular glutamate. By locally applying a competitive non-transportable 
EAAT blocker (TBOA) into the extracellular space, we examined how transient inhibition 
of glutamate uptake alters the extracellular glutamate concentration. In sham, local 
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application of TBOA produced a rapid and significant increase in the extracellular 
glutamate concentration and produced higher levels of glutamate for a longer period of 
time (area under curve) compared to local application of saline (Table 3.1). After TBI, 
local application of TBOA produced a rapid and significant increase in the extracellular 
glutamate concentration and produced higher levels of glutamate for a longer period of 
time (area under curve) compared to local application of saline (Table 3.1). Averaged 
group responses from the local application of TBOA within the striatum in both sham and 
TBI groups demonstrate increased amounts of glutamate spillover from inhibition of 
glutamate uptake after TBI (Fig 3.3A). The maximum increase in extracellular glutamate 
from local application of TBOA was significantly greater after TBI than sham [t6 = 3.391, 
p = 0.015] (Fig 3.3B). Also, after TBI more glutamate remained in the extracellular space 
for a longer period of time (area under curve) than in sham [t6 = 2.521, p = 0. 045] (Fig 
3.3C). Thus, the increased glutamate spillover from the transient inhibition of glutamate 
uptake in brain-injured animals suggests decreased glutamate uptake may play a role in 
the increase in extracellular glutamate after TBI. 
Using quantitative real-time PCR, we examined if decreased gene expression of 
glial EAATs (GLAST and GLT-1) was responsible for the increased sensitivity to the 
inhibition of the EAATs to TBOA. In the dorsal striatum, the relative expression of 
GLAST and GLT-1 was decreased, but not significantly after TBI compared to sham; 
(sham: TBI), GLAST (1.02 ± 0.13: 0.80 ± 0.06) [t6 = 1.58, p = 0.164], GLT-1 (1.01 ± 0.06: 
0.84 ± 0.16) [t6 = 0.95, p = 0.378]. Thus, any injury-related changes in glial glutamate 
transporters are not evident as changes in gene expression. 
 
Decreased glutamate clearance in the striatum of brain-injured rats 
We further explored post-traumatic decreases in glutamate uptake by examining 
how sham and brain-injured animals were able to clear exogenous applications of 
glutamate within the striatum. Local application of small volumes of glutamate into the 
extracellular space, allowed us to mimic endogenous glutamate release and examine 
clearance of glutamate back to baseline values. The primary mechanism for removing 
glutamate from the extracellular space is glutamate uptake via EAATs. Diffusion of 
glutamate also plays a role in lowering the extracellular glutamate concentration, but is 
limited by the extracellular anatomy (Danbolt 2001). Representative recordings 
demonstrate slower glutamate clearance after TBI than sham (Fig 3.4A). Since the 
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amplitude of the glutamate signals were similar between sham (30.4 ± 1.6 µM) and TBI 
(32.4 ± 1.9 µM) [t14 = 0.8139, p = 0.429] (Fig 3.4B), we compared specific parameters of 
glutamate clearance (Nickell, et al. 2007, Thomas, et al. 2009, Thomas, et al. 2011). 
After local application of glutamate, glutamate levels spike and rapidly returned to 
baseline concentrations as glutamate diffused from the local area and through uptake of 
glutamate from the extracellular space. We calculated the Trise, the time for the signal to 
reach the maximum amplitude, to examine if injury altered diffusion of glutamate in the 
extracellular space. The Trise was not significantly altered after TBI (1.8 ± 0.1 s) 
compared to sham (1.9 ± 0.1s) [t14 = 1.129, p = 0.278] (Fig 3.4C). Since, no differences 
in diffusion were detected after injury, any reductions in glutamate clearance likely result 
from decreases in glutamate uptake. TBI produced a significant decrease in k-1, a 
measure of glutamate uptake, (0.31 ± 0.05 s-1), compared to sham (0.48 ± 0.07 s-1) [t14 = 
2.166, p = 0.048] (Fig 3.4D). Also, TBI produced a significantly longer T80, time for the 
signal to decay by 80% from the peak amplitude (4.5 ± 0.6 s), compared to sham (3.2 ± 
0.2 s) [t14 = 2.184, p = 0.047] (Fig 3.4E). Thus, TBI produced significant decreases in 
glutamate clearance, without altering diffusion rates of extracellular glutamate between 
sham and TBI. Functional decreases in glutamate uptake are likely to be a primary 
mechanism responsible for increased extracellular glutamate after TBI. 
 
Discussion 
The purpose of this study was to examine the regulation of extracellular 
glutamate by both neurons and glia to determine the specific mechanism(s) responsible 
for the increase in extracellular glutamate in the rat striatum two days after diffuse brain 
injury. By combining glutamate-sensitive MEAs with targeted pharmacological agents, 
we were able to examine the neuronal and glial contributions to the release and 
regulation of extracellular glutamate. In sham animals, presynaptic calcium channel-
dependent neuronal glutamate release significantly contributed to extracellular 
glutamate. Glia were also found to regulate extracellular glutamate as inhibition of 
EAATs produced a significant increase in extracellular glutamate. Two days after diffuse 
brain injury, we detected significant post-traumatic disruptions in the regulation of 
extracellular glutamate by both neurons and glia. In brain-injured animals, the 
contribution of presynaptic calcium channel-dependent neuronal glutamate release to 
extracellular glutamate was significantly decreased compared to sham. In addition, TBI 
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produced increased glutamate spillover from the inhibition of glutamate uptake in the 
striatum of brain-injured rats. Furthermore, brain-injured animals exhibited slower 
clearance of extracellular glutamate due primarily to decreases in glutamate uptake, yet 
not necessarily due to decreases in GLAST and GLT-1 gene expression. These results 
are depicted in schematic format to highlight possible sites of dysregulation in the injury-
induced increase in extracellular glutamate (Fig 3.5). 
Calcium channel-dependent neuronal glutamate release contributes extracellular 
glutamate in sham animals 
In sham animals, local application of ω-conotoxin produced a significant ~80% 
decrease in extracellular glutamate, suggesting that a majority of extracellular glutamate 
measured by MEAs is of a neuronal origin. This result is similar to another study using 
MEAs, where local application of ω-conotoxin (mixed channel type) produced a 
significant ~50% decrease in the extracellular glutamate concentration in awake freely 
moving animals (Hascup, et al. 2010). Collectively, these results confirm that MEAs 
measure extracellular glutamate derived, in part, from calcium-dependent neuronal 
release. In contrast to the MEA studies, extracellular glutamate sampled by microdialysis 
is insensitive to sodium/calcium channel blockers; suggesting the extracellular pool of 
glutamate sampled with microdialysis is of a non-neuronal origin (Timmerman and  
Westerink 1997). The discrepancy that MEAs detect neuronally derived glutamate, 
whereas microdialysis samples extracellular glutamate derived from non-neuronal 
origins, may be due to inherent differences in the methodologies. The extensive damage 
to the local brain area during implantation of the microdialysis probe and the large area 
of tissue sampled (1-4 mm in length), restricts microdialysis measurements of glutamate 
to large regions far beyond synapses (Timmerman and  Westerink 1997, Obrenovitch 
1999, Obrenovitch, et al. 2000, Borland, et al. 2005, Hillered, et al. 2005, Jaquins-Gerstl 
and  Michael 2009). Furthermore, the inadequate temporal resolution of microdialysis 
(~1-20 min) prevents microdialysis from detecting the rapid dynamic changes in 
extracellular glutamate that occur in the order of milliseconds to seconds (Diamond 
2005). The improved spatial resolution (333 µm in length), limited damage to the local 
area from implantation of the device and fast temporal resolution (2 Hz) allow MEAs to 
detect the fast dynamics of glutamate closer to synapses and detect extracellular 
glutamate that is neuronally derived (Day, et al. 2006, Hascup, et al. 2007, Rutherford, et 
al. 2007, Hascup, et al. 2009, Hascup, et al. 2010). 
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Reduced calcium channel-dependent neuronal glutamate release in brain-injured 
rats 
In contrast to sham animals, local application of ω-conotoxin failed to significantly 
reduce the extracellular glutamate concentration compared to saline after TBI. This shift 
in the source of glutamate release from neuronal sources in sham to non-neuronal 
sources after TBI could be explained by two different mechanisms. First, there could be 
a post-traumatic decrease in neuronal glutamate release with a concurrent increase in 
non-neuronal sources of glutamate. Non-neuronal sources of extracellular glutamate can 
include: One, micropores in cellular membranes from the primary injury forces can 
release glutamate into the extracellular space due to the higher concentrations of 
glutamate found in the cytosol or blood (Schmidt and  Grady 1993, Koizumi, et al. 1997). 
Two, activated microglia can release glutamate into the extracellular space in response 
to inflammatory cytokines after TBI (Brown and  Neher 2010). Three, glutamate can be 
released from the xc-, which may be enhanced after injury for the production of 
glutathione, a major cellular anti-oxidant (Baker, et al. 2002, Domercq, et al. 2007). Four, 
EAATs can reverse due to ionic and metabolic disruptions after TBI transporting 
glutamate into the extracellular space (Gemba, et al. 1994, Phillis, et al. 2000, Hamann, 
et al. 2002). Overall, the observed reduction in presynaptic calcium channel-dependent 
vesicular glutamate release after TBI may be a compensatory mechanism for increases 
in non-vesicular sources of glutamate. 
A second mechanism that may contribute to the decrease in presynaptic calcium 
channel-dependent glutamate release after TBI is a post-traumatic alteration in the 
mechanism of vesicular glutamate release that is independent of calcium entry through 
the N-type calcium channel. Neurons are capable of vesicular release independent of 
calcium entry from the extracellular space, as internal calcium stores can mobilize from 
the mitochondria and endoplasmic reticulum for vesicular release (Ryglewski, et al. 
2007, Neher and  Sakaba 2008). After midline FPI, neurons have exhibited disrupted 
calcium regulation with increasing intracellular calcium levels (Sun, et al. 2008, McGinn, 
et al. 2009). The disrupted internal calcium regulation and a post-traumatic shift utilizing 
internal calcium stores for vesicular glutamate release may explain why blocking the N-
type calcium channel with ω-conotoxin failed to reduce extracellular glutamate in brain-
injured animals.  
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Neuronal regulation of extracellular glutamate (mGluR2/3) 
Transient activation of the glutamate autoreceptors (mGluR2/3) has been reported 
to regulate neuronal glutamate release (Bond, et al. 1999), potentially restoring 
extracellular glutamate levels in the injured brain. The mGluR2/3’s are G-protein linked 
receptors that negatively regulate adenylate cyclase and decrease levels of cyclic 
adenosine monophosphate (Danbolt 2001). The mGluR2/3 act as negatively coupled 
autoreceptors providing presynaptic inhibition of glutamate release (Nakanishi 1994, Di 
Iorio, et al. 1996, Battaglia, et al. 1997, Allen, et al. 1999, Schoepp 2001). In sham 
animals, local application of LY 379268 failed to significantly reduce extracellular 
glutamate compared to saline. Whereas, a previous study in awake animals detected a 
significant ~20% decrease in the extracellular glutamate from local application of LY 
379268 (Hascup, et al. 2010). The discrepancy between our results and the 
aforementioned study may be due to confounding effects of anesthesia, as urethane has 
been shown to dramatically reduce extracellular glutamate by ~60-80% (Rutherford, et 
al. 2007). 
We hypothesized that local transient activation of mGluR2/3 would reduce 
excessive synaptic glutamate release and lower extracellular glutamate, as we have 
previously shown increased amounts of neuronal glutamate release from local 
depolarization in the rat striatum two days after TBI (Hinzman, et al. 2010). Furthermore, 
multiple reports have shown LY 379268 to be neuroprotective in ischemia and TBI 
models (Cai, et al. 1999, Bond, et al. 2000, Stover, et al. 2003, Movsesyan and  Faden 
2006). However, in brain-injured animals transient local application of LY 379268 failed 
to reduce extracellular glutamate compared to saline. The inability of LY 379268 to 
reduce extracellular glutamate was also seen in a prior study, where a single i.p. 
injection of LY 379268 improved EEG activity, reduced contusion volume, but failed to 
reduce extracellular glutamate; suggesting LY 379268 works through other mechanisms 
to provide neuroprotection than solely reducing extracellular glutamate (Stover, et al. 
2003). 
 
Glial source of extracellular glutamate (xc-) 
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We also examined glial glutamate release through the xc-, a potential non-
neuronal source of extracellular glutamate, by locally applying xc- blocker (CPG). The xc-, 
predominantly localized to glia, is an anti-porter internalizing cystine with simultaneous 
release of glutamate; xc- plays a vital role in the prevention of oxidative damage by 
importing cystine for the production of glutathione, a major anti-oxidant in the cell 
(Albrecht, et al. 2010). The xc- has been proposed as a major source of extracellular 
glutamate with CPG producing a significant ~60% decrease in extracellular glutamate 
sampled by microdialysis (Baker, et al. 2002). In our study, local application of CPG 
failed to significantly reduce extracellular glutamate compared to saline in both sham 
and TBI animals. Similar to our data, multiple reports have detected no significant 
change in extracellular glutamate with application of CPG in both anesthetized and 
awake animals (Melendez, et al. 2005, Hascup, et al. 2010, Lupinsky, et al. 2010). In 
general, the data reported here and from prior reports suggest a limited role for the xc- as 
a source of extracellular glutamate. 
 
Glutamate uptake through EAATs regulates extracellular glutamate 
In sham animals, we examined the role of EAATs on regulating extracellular 
glutamate by locally applying the EAAT competitive blocker, TBOA. Local application of 
TBOA into the extracellular space produced a robust increase in the extracellular 
glutamate concentration as TBOA inhibited glutamate uptake by the EAATs allowing 
more glutamate to escape from the synapses. Prior studies, using both microdialysis and 
MEAs have detected similar increases in the extracellular concentration of glutamate 
with inhibition of EAATs which equates to increases in extracellular glutamate ranging 
from ~125-800% (Montiel, et al. 2005, Day, et al. 2006, Tovar, et al. 2009, Hascup, et al. 
2010). Collectively, our data and the previous reports support the importance of EAATs 
in regulating extracellular glutamate.  
 
Increased glutamate spillover from the inhibition of glutamate uptake in brain-
injured rats 
Similar to sham animals, in brain-injured animals local application of TBOA into 
the extracellular space produced a robust increase in extracellular glutamate. In addition, 
TBI resulted in a significantly greater increase in the amount of glutamate spillover from 
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the synapses of brain-injured animals compared to sham. The increase in glutamate 
spillover when challenged with an uptake inhibitor suggests either a post-traumatic 
decrease in EAATs expression or function. Although we did not detect a significant 
decrease in the expression of GLAST and GLT-1 genes; multiple reports have detected 
post-traumatic reductions in the expression of EAATs in both the clinic and experimental 
models of TBI (Rao, et al. 1998, van Landeghem, et al. 2001, Yi, et al. 2005, van 
Landeghem, et al. 2006, Yi and  Hazell 2006).  
 
Decreased glutamate clearance in brain-injured rats 
Rapid application of glutamate into the extracellular space allowed us to mimic 
endogenous glutamate release events and examine the ability of EAATs to take up 
glutamate in vivo. Here, we report significant decreases in glutamate clearance after 
TBI. The post-traumatic decrease in glutamate clearance seems to be due to decreases 
in glutamate uptake and not due to alterations in the diffusion of glutamate within the 
extracellular space. If TBI drastically altered the tortuosity of  the extracellular space, we 
would expect a post-traumatic change in the diffusion of glutamate in the extracellular 
space (Nicholson, et al. 2000). However, we detected no significant change in the Trise 
as glutamate diffused from the point source (micropipette) to the MEA, suggesting the 
decreased glutamate clearance is due to decreased glutamate uptake. Post-traumatic 
reductions in glutamate uptake can play a pivotal role in the pathophysiology of TBI over 
stimulating metabotropic and ionotropic glutamate receptors. Peri-contusional tissue 
exhibits decreased expression of EAATs in both the clinic and experimental models of 
TBI (Rao, et al. 1998, van Landeghem, et al. 2001, Yi, et al. 2005, van Landeghem, et 
al. 2006, Yi and  Hazell 2006). Furthermore, knockdown expression of GLAST and GLT-
1 produces increased neuronal damage in an experimental model of TBI (Rao, et al. 
2001). These studies demonstrate the importance of maintaining proper glutamate 
uptake to prevent the initiation and propagation of secondary injury cascades and 
development of a contusion. Early post-traumatic disruptions in glutamate clearance 
may play a role in the development of late-onset gain-of function behavioral morbidity 
that is correlated with changes in glutamate hypersensitivity (Thomas, et al. 2011). 
Although we do not know if the disruptions in the regulation of extracellular glutamate will 
hold true for later time points or indefinitely, prior work has detected persistent changes 
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in glutamate excitability in the thalamus and somatosensory cortex (Thomas, et al. 
2011). 
Decreased glutamate uptake is likely the primary mechanism for increased 
extracellular glutamate after injury. With reduced glutamate uptake, more glutamate can 
spill out from the synapse increasing extracellular glutamate over time. Furthermore, 
reduced glutamate uptake is likely responsible for the increased KCl-evoked glutamate 
release seen in our prior study (Hinzman, et al. 2010). A decrease in glutamate uptake 
would allow more glutamate to escape from the synapse, producing larger amplitudes 
during evoked release. Previously, we did not detect any post-traumatic decrease in 
glutamate clearance parameters from KCl-evoked glutamate release most likely due to 
the disruptions in the electrochemical gradient required for depolarization, which is 
circumvented by local application of glutamate itself.  
 
Conclusion 
Using MEAs and targeted pharmacological agents, we were able to examine how 
neurons and glia release and regulate extracellular glutamate in vivo. Two days after 
diffuse brain injury the contribution of calcium-mediated glutamate release via the N-type 
calcium channel was significantly reduced. Also, TBI produced a significant decrease in 
glutamate clearance that was primarily due to decreases in glutamate uptake. Future 
work should examine if enhancing expression of the EAATs, either by viral mediated 
expression or stimulating expression through the use of beta-lactam antibiotics 
(Rothstein, et al. 2005, Harvey, et al. 2011), produces an overall improvement in 
glutamate regulation and behavioral outcomes in experimental models of TBI. In 
addition, drugs that can improve the function and/or surface expression of EAATs 
remain possible therapeutic targets to improve outcomes following TBI.  
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Mary Ann Liebert, Inc.]; [Journal of Neurotrauma] is available online at: 
http://online.liebertpub.com. 
 
Copyright © Jason Michael Hinzman 2012 
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Chapter Three: Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Increased extracellular glutamate in the striatum of brain-injured rats at 
two days after midline fluid percussion brain injury 
 
Higher levels of extracellular glutamate in the straitum of brain-injured rats compared to 
sham, (n =16, * p < 0.05).  
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Figure 3.2 Reduced calcium channel-dependent glutamate release in the striatum 
of brain-injured rats 
 
(A) Baseline-matched traces of extracellular glutamate demonstrate the average effect 
of 100 nL local application (↑) of 10 µM ω-conotoxin, N-type calcium channel blocker, on 
extracellular glutamate in sham (blue) and TBI animals (red). (B) The maximum 
decrease in extracellular glutamate from local application of ω-conotoxin was 
significantly smaller after TBI than sham. (C) The extent of reduced extracellular 
glutamate with respect to time (area under curve) was significantly reduced after TBI 
than sham (n = 4, * p < 0.05). 
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Figure 3.3 Increased glutamate spillover from inhibition of glutamate uptake in the 
striatum of brain-injured rats 
 
(A) Traces of extracellular glutamate showing the average response from 100 nL local 
application (↑) of 100 µM TBOA, excitato ry amino acid transporter blocker, in sham 
(blue) and TBI (red). (B) The maximum increase in extracellular glutamate from local 
application of TBOA was significantly elevated after TBI compared to sham. (C) The 
extent of higher extracellular glutamate with respect to time (area under curve) was 
significantly increased after TBI than sham (n = 4, * p < 0.05). 
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Figure 3.4 Decreased glutamate clearance in the striatum of brain-injured rats 
 
(A) Representative glutamate signals in the striatum from local application of 500 µM 
glutamate (↑) in sham (blue ) and TBI (red) showed significant decreases in glutamate 
uptake parameters after TBI. (B) The amplitude of the glutamate signal was similar 
between sham and TBI groups. (C) Trise, an indicator of glutamate diffusion, was similar 
between sham and TBI groups. (D) k-1, an indicator of glutamate uptake rate, was 
significantly reduced after TBI compared to sham. (E) T80, an indicator of glutamate 
clearance, was significantly longer after TBI compared to sham (n = 8, * p < 0.05). 
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Figure 3.5 Schematic depicting the regulation of extracellular glutamate in the rat 
striatum in sham and brain-injured animals 
 
In sham animals, neurons release glutamate into the extracellular space that is 
dependent on calcium entry through N-type calcium channels. Once in the extracellular 
space, glutamate acts on both metabotropic and ionotropic glutamate receptors for 
signal propagation. Glutamate is removed from the extracellular space by excitatory 
amino acid transporters, predominantly localized to glia. Glutamate uptake is the primary 
mechanism for removal of extracellular glutamate and is responsible for regulating the 
concentration extracellular glutamate. After TBI, we detected post-traumatic disruptions 
in the regulation of extracellular glutamate by both neurons and glia. In brain-injured 
animals, calcium-dependent glutamate release via N-type calcium channels was no 
longer a source of extracellular glutamate. Also, the uptake of glutamate by excitatory 
amino acid transporters was reduced in brain-injured animals. Post-traumatic decreases 
in glutamate uptake is likely the primary mechanism responsible for increased 
extracellular glutamate after TBI. 
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Chapter Three: Tables 
 
Table 3.1 Effect of local application of drugs on extracellular glutamate in sham 
and traumatic brain injured (TBI) animals 
 
Local 
Application 
                                                 
Maximum Change From 
Baseline Glutamate (µM) 
Area Under Curve                          
(AU) 
Sham TBI Sham TBI 
saline -0.7 ± 0.2 -0.4 ± 0.1 40.7 ± 21.1 11.6 ± 5.1 
ω-conotoxin -2.6 ± 0.8* -0.4 ± 0.1 343.8 ± 97.8* 33.7 ± 18.6 
saline 0.4 ± 0.4 1.0 ± 0.1 2.4 ± 2.1 2.3 ± 2.3 
TBOA 5.2 ± 1.7* 8.5 ± 0.8* 26.3 ± 5.3* 53.6 ± 9.4* 
 
 
Mean ± SEM; * p <0.05 (treatment vs. saline); n=4 
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Preface to Chapter Four  
In the previous chapters I have demonstrated disruptions in the regulation of 
extracellular glutamate after diffuse brain injury. The aim of the experiments in Chapter 
Four was to examine a novel approach to improve the regulation of extracellular 
glutamate. Using a viral vector-mediated gene delivery approach, we examined if 
infusion of adeno-associated virus expressing glutamate transporter-1 (AAV-GLT-1) 
could produce targeted expression of functional GLT-1 and improve the regulation of 
extracellular glutamate in the rat striatum. 
 
Chapter Four: Targeted expression of the glutamate transporter, GLT-1, in 
the rat striatum using a viral vector-mediated gene delivery approach 
 
 
Abstract 
Glutamate neurotransmission is involved in almost all aspects of neurological 
function. Dysregulated glutamate signaling has been implicated in a host of 
neurodegenerative and neuropsychiatric disorders. Increases in extracellular glutamate 
can excessively activate glutamate receptors producing excitotoxicity. To prevent 
excitotoxic accumulation of extracellular glutamate, the central nervous system has 
developed an abundant system of glutamate transporters to regulate extracellular 
glutamate. The purpose of this study was to examine if a viral vector-mediated gene 
delivery approach, adeno-associated virus (AAV), could target the expression of 
functional glutamate transporter (GLT-1) in the rat striatum. To examine the expression 
of functional GLT-1, glutamate-sensitive microelectrode arrays (MEAs) were used to 
measure clearance kinetics of locally applied glutamate into the extracellular space in 
rats infused with either AAV-GLT-1 or AAV-GFP (green fluorescent protein).  Three 
weeks after viral infusion, the clearance of glutamate was significantly faster in the 
striatal hemisphere infused with AAV-GLT-1/RFP (red fluorescent protein) than the 
hemisphere infused with AAV-GFP. Thus, using a viral vector-mediated gene delivery 
approach, we were able to increase glutamate clearance, indicating increased 
expression of functional GLT-1. Overall, these data suggest a novel therapeutic strategy 
to improve glutamate uptake, which may improve glutamate regulation and reduce 
excitotoxicity. 
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Introduction 
Glutamate, the predominant excitatory neurotransmitter in the central nervous 
system, is involved in almost all aspects of neurological function including cognition, 
motor function, memory, learning, decision making, and neuronal plasticity (McEntee 
and  Crook 1993, Danbolt 2001). For normal neurological function, glutamate signaling 
must be properly regulated. Glutamate is released into the extracellular space where 
glutamate binds to both metabotropic and ionotropic glutamate receptors for propagation 
of the excitatory signal (Jabaudon, et al. 1999, Jensen, et al. 2000). Appropriate 
activation of glutamate receptors requires tight regulation of the extracellular 
concentration of glutamate. Concentrations of extracellular glutamate are maintained low 
by the uptake of glutamate via five high affinity sodium-dependent excitatory amino acid 
transporters (EAATs), GLAST, GLT-1, EAAC, EAAT4, and EAAT5 (Danbolt 2001). A 
majority (~90%) of glutamate uptake is performed by two glial transporters in the rat 
forebrain, GLAST and GLT-1 (Rothstein, et al. 1996, Tanaka, et al. 1997, Danbolt 2001).  
Dysregulated glutamate signaling has been implicated in a host of neurological 
and neuropsychiatric disorders including TBI, stroke, Parkinson’s disease, Alzheimer’s 
disease, Huntington’s disease, amyotrophic lateral sclerosis, epilepsy, schizophrenia, 
drug addiction, anxiety and depression (Doble 1999, Danbolt 2001, Nanitsos, et al. 
2005, Mathew, et al. 2008, McNally, et al. 2008). Disruptions in the regulation of 
extracellular glutamate can produce increases in extracellular glutamate excessively 
activating glutamate receptors. Excessive stimulation of glutamate receptors can induce 
“excitotoxicity”, a neuropathological processes involving prolonged neuronal 
depolarization, increases in intracellular calcium concentration, and activation of 
enzymatic mechanisms of cell death (Olney and  de Gubareff 1978, Faden, et al. 1989, 
Doble 1999, Doyle, et al. 2008). Excitotoxicity is thought to be one of the predominant 
pathophysiological processes involved in neuronal damage and death in traumatic brain 
injury and stroke as excitotoxic concentrations of glutamate have beed detected in 
stroke and TBI survivors (Bullock, et al. 1995, Davalos, et al. 2000).   
Inhibiting excitotoxicity through the use of glutamate receptor antagonists has 
been a therapeutic strategy for the treatment of stroke and traumatic brain injury for 
many years (Willis, et al. 2004, Muir 2006, Garber 2007). Multiple studies have reported 
reduced damage and improved outcomes with the use of glutamate receptor antagonist 
in experimental models of stroke and traumatic brain injury (Simon, et al. 1984, 
Sheardown, et al. 1990, Myseros and  Bullock 1995, Shen, et al. 2005, Shen, et al. 
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2009). However, glutamate receptor antagonists have failed to translate into positive 
clinical outcomes due to a lack of efficacy and/or adverse effects in the central nervous 
system (Bullock 1995, Ikonomidou and  Turski 2002, Hoyte, et al. 2004, Villmann and  
Becker 2007). Taken together, these results support the examination of alternate 
strategies to improve the regulation of extracellular glutamate, which may produce the 
same beneficial effects while limiting the adverse effects observed with glutamate 
receptor antagonist.  
Intraperitoneal administration of a beta-lactam antibiotic, ceftriaxone, has been 
shown to increase the expression of glutamate transporters in the rat brain, and reduce 
neuronal damage and improve behavioral recovery in a rat  model of stroke (Rothstein, 
et al. 2005, Chu, et al. 2006, Chu, et al. 2007). These results suggest strategies that 
increase functional glutamate transporter levels can improve the regulation of 
extracellular glutamate and limit excitotoxicity. The purpose of this study was to examine 
if a novel approach, viral vector-mediated gene delivery of GLT-1 using an adeno-
associated virus (AAV), could target the expression of functional GLT-1 in the rat 
striatum. Furthermore, we examined two different strategies of infusing the viral-vectors 
to determine which infusion method produced the optimal distribution and expression of 
GLT-1. In the first study, we examined whether a single infusion of AAV-GLT-1/RFP, 
expressing both the glutamate transporter and red fluorescent protein, would express 
functional GLT-1 in the rat striatum. In the second study, we examined whether infusing 
AAV-GLT-1 in multiple locations within the striatum would enhance the expression and 
distribution of functional GLT-1. To examine the expression of functional GLT-1, 
glutamate-sensitive microelectrode arrays (MEAs) measured the clearance of glutamate 
locally applied into the extracellular space three weeks after infusions. 
 
Materials and Methods 
 
Animals 
In the first study, male Fischer 344 rats (n=3, Harlan Laboratories Inc., IN) were 
used, weighing 250-350 g at the time of infusion. In the second study, male Sprague-
Dawley rats (n= 12, Harlan Laboratories Inc.) were used, weighing 250-350 g at the time 
of infusion. The animals were housed in a 12 h light/dark cycle with food and water 
available ad libitum and handled in accordance with guidelines from the Guide for the 
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Care and Use of Laboratory Animals (7th edition) and to the Association for Assessment 
and Accreditation of Laboratory Animal Care International. Animals were acclimated to 
their environment for at least one week before any experiments. After infusion, animals 
were monitored daily for post-operative care. Animal care was approved by the 
University of Kentucky Institutional Animal Care and Use Committee. 
 
Construction, packaging, purification and titering of AAV vectors 
The rat complimentary DNA (cDNA) for GLT-1 was first polymerase chain 
reaction (PCR) amplified from pc-GLT-1(Pines, et al. 1992) (from Dr.  Mike Robinson at 
U. Pennsylvania). The amplified PCR product contained BamHI (5’ end) and XbaI (3’ 
end) restriction enzyme sites used to insert the PCR product into pCR8/GW/TOPO 
(Invitrogen, CA) as an intermediate. The BamHI/Xba1 fragment replaced GFP in the 
BamHI/XbaI digestion of pssAAV-GFP (Lowery, et al. 2009) to create pssAAV-GLT1.  
Viral stocks of AAV-GLT1 serotype 1 were prepared using the triple-transfection method 
(Xiao, et al. 1998, Howard, et al. 2008, Lowery, et al. 2009). Virus was provided by Dr. 
Brandon Harvery, National Institute on Drug Abuse (NIDA).   
 
Intracerebral AAV injections 
 Rats were anesthetized with 3% isoflurane, and placed in a stereotaxic frame 
(Kopf Instruments, Tujunga, CA). Animal body temperature was maintained at 37°C with 
a heating pad (Braintree Scientific, Braintree, MA) and the animals’ eyes were lubricated 
with artificial tears (The Butler Company, OH). The skin directly on top of the animal’s 
head was cleaned with a betadine solution. Then a small incision was made over the 
skull to reflect the skin.  Burr holes were drilled into the skull to provide access for the 
infusion of the virus. Before loading the syringe, the virus was sonicated for 10 s, and 
then loaded into a Hamilton syringe (33 gauge) (Hamiltion Company, NV). The needle 
was stereotaxically placed into the area of interest with a two minute waiting period 
before starting the infusion. Virus was infused at a flow rate of 0.5 µl/min using an 
injection pump (UMP2; World Precision Instruments, FL) with a two minute waiting 
period before removal of the syringe. The burr holes were sealed with bone wax and 
skin sutured. Surgeries were performed with assistance from Dr. Brandon Harvey, NIDA.  
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For the single infusion, burr holes were drilled bilaterally for infusion of the virus into the 
striatum (AP: +1.0, ML: +/- 2.5, DV: -4.5). Each hemisphere received either 3 µl of AAV-
GFP or AAV-GLT-1/RFP (Fig 4.1).  
For the multiple infusions, burr holes were drilled bilaterally to provide access for 
infusion of the virus into the striatum, and 2 µl of virus was infused into four locations in 
each hemisphere (AP: +0.5, ML: 2.0 and 3.5, DV: -4.0 and -5.0). Each hemisphere 
received a total of 8 µl of AAV-GFP or AAV-GLT-1 (Fig 4.2). 
 
Enzyme-based microelectrode arrays 
Ceramic-based microelectrode arrays (MEAs) consisting of four platinum 
recording sites (15 x 333 µm) arranged in dual pairs were prepared and selected for in 
vivo recordings as previously described, (Burmeister, et al. 2002, Day, et al. 2006, 
Hascup, et al. 2007, Stephens, et al. 2009, Hinzman, et al. 2010, Hinzman, et al. 2012). 
Two different coatings were applied to the MEAs. One pair of recording sites was coated 
with glutamate-oxidase to allow for the enzymatic conversion of glutamate to α-
ketoglutarate and the reporter molecule H2O2. Constant potential amperometry was 
performed at a potential + 0.7 V versus a silver/silver chloride reference to oxidize H2O2 
yielding two electrons. The resulting current was amplified and digitized by the FAST-16 
mkII system (Fast Analytical Sensor Technology Mark II; Quanteon, L.L.C., KY). The 
other pair of recording sites (Sentinel sites) was coated with an insensitive protein matrix 
of bovine serum albumin and glutaraldehyde to measure any background current. The 
application of two different coatings allowed the use of a self-referencing technique, 
where the current from sentinel sites could be subtracted from the current from the 
glutamate-oxidase sites thus producing a more selective glutamate measure. A size 
exclusion layer of 1,3-phenylenediamine (mPD) was electroplated to the platinum 
recording sites blocking interferents such as ascorbic acid (AA) and dopamine (DA) from 
reaching the platinum recording sites (Hinzman, et al. 2010, Thomas, et al. 2011, 
Hinzman, et al. 2012). 
 
MEA/micropipette assembly 
For local application of glutamate into the rat brain, glass micropipettes (1 mm 
o.d. 0.58 mm i.d., A-M Systems, Inc., WA) were pulled (Kopf Instruments, CA), and the 
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tips of the micropipettes were bumped to create a tip with an i.d. of 10-15 µm. The 
micropipettes were placed centrally among all four platinum recording sites and mounted 
50-100 µm above the MEA. Micropipettes were filled with 500 µM or 1 mM glutamate 
(Sigma-Aldrich, MO), dissolved in physiological saline. Solutions were sterile filtered 
(0.20 µm) and adjusted to a pH of 7.4. The micropipette was connected to a Picospritzer 
III (Parker-Hannifin, OH) with settings adjusted to consistently deliver volumes between 
12.5-350 nL. Pressure was applied from 2-30 psi for 0.3-1.0 sec. Volume displacement 
was monitored with the use of a stereomicroscope fitted with a reticule to determine and 
control the volume of solution that was locally applied by pressure ejection (Friedemann 
and  Gerhardt 1992). 
 
In vivo anesthetized recordings of extracellular glutamate 
Three weeks after viral infusion, rats were anesthetized with urethane (1.25 g/kg 
i.p.) and prepared for in vivo electrochemical recordings as previously described (Day, et 
al. 2006, Hascup, et al. 2007, Stephens, et al. 2009, Thomas, et al. 2009, Hinzman, et 
al. 2010, Thomas, et al. 2011, Hinzman, et al. 2012). Briefly, MEAs were calibrated the 
morning of the experiment and the calibration values (sensitivity, selectivity, and limit of 
detection) were comparable to previous studies.  Then, animals were placed in a 
stereotaxic frame and body temperature was maintained at ~37 °C with a water pad 
connected to a recirculating water bath. A craniotomy was performed to provide access 
to the striatum. A Ag/AgCl reference wire was implanted into the lateral parietal cortex. 
The MEA was lowered into the striatum using a microdrive (MO-10, Narishige 
International, NY). All MEA recordings were performed at a frequency of 2 Hz. 
Glutamate recordings were performed in both hemispheres comparing the AAV-GLT-1 
treated hemisphere to the AAV-GFP treated hemisphere. To examine glutamate 
clearance, varying volumes of 500 µM or 1 mM glutamate were applied into the 
extracellular space producing glutamate signals with amplitudes in the 5-200 μM range. 
Glutamate clearance was analyzed by the following parameters: (1) amplitude (μM); (2) 
T80 (s), the time for the signal to decay by 80% from the peak amplitude; (3) uptake rate 
constant k-1 (sec -1), the slope of the linear regression of the natural log transformation of 
the decay over time; and (4) clearance rate Tc (μM/sec) the slope of the line between T20 
and T60 (Nickell, et al. 2007, Thomas, et al. 2009, Hinzman, et al. 2010) (Fig 4.3).  
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In the first study, clearance of locally applied glutamate was examined 0.1 mm 
lateral to the infusion site of the virus (AP: +1.0, ML: ± 2.6, DV: -4.5), represented by * 
(Fig 4.1). In the second study, clearance of locally applied glutamate was examined in 
between the two infusion tracks at multiple depths in the striatum (AP: +0.5, ML: ± 3.3, 
DV: -4.0, -4.5 and -5.0), represented by *(Fig 4.2). 
 
Data analysis  
Amperometric data were analyzed using custom MATLAB® - based software. 
Data are presented as mean ± SEM, and statistical significance was defined as p < 0.05. 
A two-tailed t-test was used for comparisons between the AAV-GFP and AAV-GLT-1 
treated hemisphere, unless noted otherwise. 
 
Histology 
In the first study, after completion of the glutamate recordings, animals were 
transcardially perfused with physiological saline followed by 4% paraformaldehyde. 
Brains were removed and stored in 4% paraformaldehyde for 3 days. At the end of the 3 
days, the storage solution was exchanged to 0.1m phosphate buffer with 30% sucrose. 
Brains were sliced on a cryostat (0.05 mm) for visualization of GFP or RFP fluorescence. 
Histology was performed in Dr. Brandon Harvey’s Laboratory, NIDA. 
 
Quantitative gene expression (rtPCR)  
In the second study, after completion of the glutamate recordings, animals were 
transcardially perfused with cold saline, the brains rapidly removed from the skull, 
dissected into 2 mm slices using a chilled rat brain matrix, and a 2 mm diameter biopsy 
was removed from the dorsal striatum, approximate area represented in (Fig 4.2). The 
mRNA content was stabilized (RNAlater, Qiagen Corp) and stored frozen (-20◦C). 
Isolated mRNA (RNeasy, Qiagen Corp) was quantified (NanoDrop ND-1000 
spectrophotometer), converted to cDNA (High Capacity cDNA Archive Kit, Applied 
Biosystems Inc.) and then used as a template for selected commercially-available gene 
expression assays for quantitative real-time PCR (StepONE, Applied Biosystems). The 
Applied Biosystems TaqMan® Gene Expression Assays (GLT-1: Rn00568080_m1) were 
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used for GLT-1 gene expression. Within each animal, relative gene expression was 
normalized to the 18s rRNA endogenous control and the expression level in the AAV-
GFP hemisphere using the 2-ΔΔCT method (Livak and  Schmittgen 2001), which relates 
gene expression to the PCR cycle number at which the fluorescence signals exceed a 
threshold above baseline. Relative gene expression was compared between AAV-GFP 
and AAV-GLT-1 striatal punches using a two-tailed t-test.  
 
Results 
 
Single infusion of AAV- GLT-1/RFP increases expression of functional GLT-
1 in the rat striatum 
Three weeks after a single infusion of AAV-GFP or AAV-GLT-1/RFP into the rat 
striatum, we examined if viral-mediated expression could produce an increase in 
functional GLT-1. Using glutamate-sensitive MEAs we examined glutamate clearance 
0.1 mm lateral to the infusion site comparing the AAV-GLT-1/RFP treated hemisphere to 
the AAV-GFP treated hemisphere. Local application of varying amounts of 1 mM 
glutamate produced reproducible glutamate signals with amplitudes ranging from 50-200 
µM. Local application of glutamate produced a rapid increase in extracellular glutamate, 
with the signal reaching the maximum amplitude in less than 2 seconds, followed by a 
decrease in the signal as glutamate uptake restored the glutamate concentration back to 
baseline levels (Fig 4.3). Glutamate signals with similar amplitudes were used to 
compare glutamate clearance between the AAV-GFP treated hemisphere to the AAV-
GLT-1 treated hemisphere. Due to the small number of animals used in this study (n=3), 
we were only able to obtain glutamate signals with similar amplitudes in a limited range. 
Representative glutamate signals, in the 170-185 µM amplitude range, highlight the 
faster glutamate clearance rate Tc (the slope of the line between T20 and T60) in the AAV-
GLT-1/RFP striatal hemisphere compared to the AAV-GFP treated hemisphere (Fig 
4.4A). Tc was compared between AAV-GLT-1/RFP and AAV-GFP treated striatal 
hemispheres based on the amplitude of the glutamate signal. Tc was significantly 
affected by the viral treatment ANOVA [F(1,16)=31.97, p<0.0001]. The AAV-GLT-1/RFP 
treatment produced significantly faster glutamate clearance rates than AAV-GFP 
treatment in the 150-165 µM (134%) and 170-185 µM (126%) amplitude ranges 
(Bonferroni post-test, * p< 0.05, ** p< 0.01, Fig 4.4B).  
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At the conclusion of the experiment, the brains were sectioned to visually confirm 
expression and distribution of the fluorescent proteins. In a coronal section of the rat 
striatum, we were able to confirm that infusion of AAV-GLT-1/RFP and AAV-GFP 
produced expression of both red and green fluorescent proteins in their respective 
hemispheres (Fig 4.5A). At higher magnification, we were able to visualize the 
expression of GFP and RFP in both cellular bodies and elongated processes (Fig 4.5B 
and C). Thus, using a viral vector-mediated gene delivery approach, we were able to 
increase the expression of functional GLT-1 into the rat striatum.  
 
Multiple infusions of AAV- GLT-1 within the striatum failed to express 
functional GLT-1  
Three weeks after multiple infusions of AAV-GLT-1 within the rat striatum, we 
examined if infusing the virus in multiple locations within the striatum would enhance the 
viral-mediated expression and distribution of functional GLT-1 (Fig 4.2). Glutamate-
sensitive MEAs were used to examine the clearance of exogenously applied glutamate 
into the extracellular space in multiple depths of the striatum comparing the AAV-GLT-1 
treated hemisphere to the AAV-GFP treated hemisphere. Representative glutamate 
signals depict a similar decay of the glutamate signal from exogenous application of 
glutamate between the AAV-GFP and AAV-GLT-1 treated hemispheres (Fig 4.6). 
Glutamate signals were sorted based on the amplitude of the signals, (<50, 50-100, 
>100 µM), and parameters of glutamate clearance were compared between the AAV-
GFP and AAV-GLT-1 treated hemispheres. Due to the increased number of animals in 
this study (n=12) we were able to obtain glutamate signals with a larger range of 
amplitudes for comparison. In all the amplitude ranges, we detected no significant 
difference in any of the clearance parameters between the AAV-GFP and AAV-GLT-1 
treated hemispheres (Table 4.1). These data indicate that multiple infusion loci did not 
produce changes in glutamate clearance that would have been indicative of enhanced 
functional GLT-1 levels. 
At the conclusion of the experiment, we used quantitative real-time PCR to 
examine the gene expression of GLT-1. In the dorsal striatum, there was no significant 
difference in the relative expression of GLT-1 between the AAV-GFP (0.98 ± 0.2) and 
AAV-GLT-1 (1.0 ± 0.1) treated hemispheres (Fig 4.7). Thus, rt-PCR results support the 
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conclusion that multiple injections of AAV-GLT-1 into the striatum failed to increase gene 
expression of GLT-1. 
  
 
Discussion 
The purpose of this study was to examine if a viral vector-mediated gene delivery 
approach (AAV-GLT-1) could target the expression of functional GLT-1 into the rat 
striatum and thereby improve the regulation of extracellular glutamate. In the single 
infusion study, infusion of AAV-GLT-1/RFP into the striatum produced significantly faster 
glutamate clearance compared to infusion of AAV-GFP. We were able to confirm 
expression of the fluorescent protein tags RFP and GFP in their respective striatal 
hemisphere with expression of both proteins in cell bodies and elongated processes. In 
the multiple infusion study, we tried to enhance the expression and distribution of GLT-1 
by infusing AAV-GLT-1 into multiple locations within the striatum. Three weeks after 
infusion, we detected no significant difference in glutamate clearance or in the gene 
expression of GLT-1 between the AAV-GLT-1 and AAV-GFP treated hemispheres. 
Thus, using a viral vector-mediated gene delivery approach, with a single infusion of 
AAV-GLT-1/RFP, we were able to increase the expression of functional GLT-1 into the 
rat striatum.  
We have yet to identify the exact reason why multiple infusions of AAV-GLT-1 
failed to produce expression of functional GLT-1, while a single infusion of AAV-GLT-
1/RFP produced functional expression of GLT-1 in the rat striatum. In the multiple 
infusion study, we used two infusion tracks to inject the virus into four separate locations 
within the striatum. Multiple insertions of the infusion needle may have produced an 
increased amount of damage and inflammation preventing transduction of the virus into 
the cells. However, previous work by our collaborator (Dr. Brandon Harvey), achieved 
viral-mediated expression of GLT-1 using a multiple infusion design within the rat cortex 
(Harvey, et al. 2011). Another possible reason for the lack of expression in the multiple 
infusion study is due to differences in the viral vectors. In the single infusion study we 
used AAV-GLT-1/RFP while in the multiple infusion study we used AAV-GLT-1, 
differences in the construction of the viral-vectors may have produced variances in the 
titers and/or transduction efficiency between the viral-vectors. The most likely reason for 
lack of expression in the multiple infusion study is a loss of viral integrity due to problems 
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in shipping and/or preparing the AAV-GLT-1 for infusion into the striatum. In the future, 
improvements in the experimental design need to include transducing primary neuron 
cultures using the same aliquot of virus, confirming viral integrity. Also, examining both 
histology for fluorescent markers and gene expression will aide in detecting problems 
with infusion of the virus. 
In both studies, AAV sereotype 1 was used, which has been shown to transduce 
both neurons and glia (unpublished observation, Dr. Brandon Harvey). Normally GLT-1 
is only expressed on glia, so one of the overall goals of the second study was to 
examine how increased expression of GLT-1 in both neurons and glia would alter 
multiple aspects of glutamate signaling including glutamate clearance, tonic glutamate, 
and KCl-evoked glutamate release (Danbolt 2001). Since we were unable to increase 
the gene expression of GLT-1 in the second study, future work should address how 
neuronal expression of GLT-1 alters glutamate signaling and regulation.  
The overall objective of this study was to identify a novel therapeutic strategy to 
improve the regulation of extracellular glutamate that may limit or reduce excitotoxicity. 
Recent work by our collaborator (Dr. Brandon Harvey, NIDA) has shown this approach 
(AAV-GLT-1) can enhance glutamate regulation, reduce damage, and improve 
outcomes in a rat model of stroke. Intracerebral infusions of AAV-GLT-1 into three 
cortical sites in the distribution of the right middle cerebral artery prior to occlusion, 
reduced cerebral infarction, improved functional recovery, reduced ischemia-induced 
glutamate overflow, and reduced tissue damage (Harvey, et al. 2011). The above study 
validates the theory that increasing expression of glutamate transporters can improve 
glutamate regulation, reduce excitotoxicity, and improve outcomes in a model of 
excitotoxicity.    
A major advantage of using a viral vector-mediated gene delivery approach is the 
ability to target the expression of the glutamate transporter into the brain region of 
interest. Targeting the expression only in the area of interest should not alter glutamate 
signaling in other brain regions, thereby, limiting adverse effects seen with glutamate-
receptor antagonist such as hallucinations, catatonia, ataxia, nightmares, and memory 
deficits (Blanke and  VanDongen 2009). To date, a viral-vector mediated approach is the 
only known method that allows targeting the expression of a glutamate transporter into 
the brain region of interest. While administration of ceftriaxone may increase glutamate 
transporters, the increase will not be localized to a certain brain region, this may disrupt 
glutamate signaling in undesired brain regions producing adverse effects similar to those 
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observed with glutamate-receptor antagonist. Future work should thoroughly exam 
potential side effects from targeted over-expression of GLT-1. However, a recent study 
detected no significant changes in locomotor activity after multiple infusion of AAV-GLT-
1 in the rat cortex (Harvey, et al. 2011).  
A major disadvantage of using a viral vector-mediated gene delivery approach is 
the approximate three weeks needed for stable expression of the protein. In our studies, 
AAV-GLT-1 was infused three weeks prior to testing to allow for stable expression. The 
other known method to increase the expression of glutamate transporters, 
intraperitoneal injection of ceftriaxone, takes approximately five days of daily 
administration (Rothstein, et al. 2005). The relatively long period amount of time needed 
for stable expression of the glutamate transporters by both methods severely inhibits 
their potential as a viable treatment to reduce the acute excitotoxicty in stroke and TBI, 
which occurs within the first few days (Bullock, et al. 1995, Davalos, et al. 2000). Another 
disadvantage of using a viral-vector approach to increase expression of GLT-1 is the 
inability to modulate or stop expression after infusion, especially if unwanted side effects 
started to occur.  
In conclusion, we have used a viral-vector mediated gene delivery approach to 
target the expression of functional GLT-1 into the rat striatum. Recent data supports 
improving glutamate regulation in pathologies where glutamate is elevated through the 
upregulation of glutamate transporters can protect against excitotoxicity and improve 
behavioral outcomes in animal models of stroke (Rothstein, et al. 2005, Chu, et al. 2006, 
Chu, et al. 2007, Harvey, et al. 2011). Further development of selective gene delivery 
may make the use of GLT-1 a more viable therapeutic strategy to treat neurological and 
neuropsychiatric disorders involving chronic dysregulation of extracellular glutamate in 
discrete brain areas. Future work is needed to identify strategies that rapidly increase 
the expression of glutamate transporters as this appears to be a promising therapeutic 
strategy to limit acute excitotoxicity and improve outcomes in traumatic brain injury and 
stroke survivors. 
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Portions of Chapter Four have been published in the following manuscript:  
Harvey BK, Airavaara M, Hinzman J, Wires EM, Chiocco MJ, Howard DB, Shen H, 
Gerhardt G, Hoffer BJ, Wang Y. Targeted over-expression of glutamate transporter 1 
(GLT-1) reduces ischemic brain injury in a rat model of stroke. PLoS One. 
2011;6(8):e22135. Epub 2011 Aug 10. 
Permission to publish in this thesis falls within PLoS One open access agreement. 
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Chapter Four: Figures 
Figure 4.1 Representation of the sites for the viral infusion and glutamate 
recordings in the rat striatum 
 
The diagram shows the approximate location of the viral infusion sites for AAV-GFP 
(green circle) and AAV-GLT-1/RFP (red circle) and the approximate location of the 
glutamate recording in the rat striatum (*). Bilateral recordings were conducted for 
glutamate clearance comparing the AAV-GFP and AAV-GLT-1/RFP treated 
hemispheres. 
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Figure 4.2 Representation of the sites for the viral infusion, glutamate recordings, 
and tissue punches for gene expression in the rat striatum 
 
The diagram shows the approximate location of the viral infusion sites for AAV-GFP 
(green circle) and AAV-GLT-1 (red circle) and the approximate location of the glutamate 
recording sites in the rat striatum (*). Bilateral recordings were conducted for glutamate 
clearance in multiple depths of the striatum comparing the AAV-GFP and AAV-GLT-
1/RFP treated hemispheres. Striatal tissue punches (grey circle) were taken to examine 
gene expression for GLT-1 using quantitative real-time PCR. 
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Figure 4.3 Representative in vivo recording from a glutamate-oxidase site and 
sentinel site of the MEA  
 
Local application of various volumes of glutamate into the extracellular space (↑) 
produced signals with a wide range of amplitudes. For each signal glutamate clearance 
was analyzed using the following parameters: amplitude, k-1, T80, and Tc. Parameters are 
shown separately for clarity.  
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Figure 4.4 Faster glutamate clearance in AAV-GLT-1 treated hemisphere compared 
to AAV-GFP hemisphere  
 
(A) Graph comparing the time course of glutamate clearance from signals with similar 
amplitudes in the 170-185 µM range. The GLT-1/RFP-treated hemisphere showed a 
faster time course of glutamate clearance compared to the GFP/RFP-treated 
hemisphere. Local application of 250 nL of 1 mM glutamate (↑) produced a robust 
increase in extracellular glutamate that returned back to baseline levels through 
glutamate uptake. Note that the Tc was significantly increased in the GLT-1/RFP 
hemisphere. (B) Faster glutamate Tc’s in the striatal hemisphere treated with GLT-1/RFP 
than the GFP/RFP-treated hemisphere. Glutamate signals were sorted by amplitude for 
comparison (* p< 0.05, ** p< 0.01, n=3).  
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Figure 4.5 Expression of green  and red fluorescent protein in the striatum three 
weeks after infusion of AAV-GFP and AAV-GLT-1/RFP 
 
(A) Coronal section of the rat striatum three weeks after infusion of AAV-GFP and AAV-
GLT-1/RFP depicting the recording track of the MEA (scale bar = 2 mm). (B) High 
magnification image of striatal hemisphere infused with AAV-GFP showing cells and 
elongated process expressing green fluorescent protein (scale bar = 0.2 mm). (C) High 
magnification image of striatal hemisphere infused with AAV-GLT-1/RFP showing cells 
and elongated process expressing red fluorescent protein (scale bar = 0.2 m 
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Figure 4.6  Similar rates of glutamate clearance in the AAV-GFP and AAV-GLT-1 
treated hemispheres  
 
Graph depicting glutamate signals with similar amplitudes (<50 µM) resulting from local 
application of glutamate (↑) at three weeks post-AAV-GFP and AAV-GLT-1 infusion. The 
clearance of the glutamate signal was similar between the AAV-GFP and AAV-GLT-1 
treated hemispheres.  
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Figure 4.7 Similar amounts of GLT-1 gene expression between the AAV-GFP and 
AAV-GLT-1 treated hemispheres 
 
Quantitative real-time PCR on striatal punches shows similar amounts of GLT-1 gene 
expressions between the AAV-GFP and AAV-GLT-1 treated hemispheres (n= 6). 
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Chapter Four: Tables 
 
Table 4.1 Comparison of glutamate clearance between the AAV-GFP and AAV-
GLT-1 treated hemispheres 
 
Amplitude    
Range  
Amplitude 
(µM) 
k-1                                       
(s-1) 
T80                                          
(s) 
Tc                               
(µM/s) 
(<50µM) 
AAV-GFP (n=22) 29.4 ± 1.8 0.22 ± 0.03 5.7 ± 0.4 6.4 ± 0.8 
AAV-GLT-1 (n=25) 25.1 ± 1.9 0.24 ± 0.02 5.4 ± 0.6 6.2 ± 0.6 
(50-100µM) 
AAV-GFP (n=17) 72.8 ± 2.7 0.28 ± 0.04 7.0 ± 1.1 14.8 ± 1.7 
AAV-GLT-1 (n=12) 70.8 ± 3.0 0.30 ± 0.04 6.3 ± 0.9 15.2 ± 2.0 
(>100µM) 
AAV-GFP (n=7) 153.1 ± 6.9 0.38 ± 0.06 5.3 ± 0.7 34.7 ± 4.9 
AAV-GLT-1 (n=7) 126.2 ± 3.4 0.37 ± 0.06 7.3 ± 1.6 29.3 ± 3.8 
 
Data shown as mean ± SEM, n= recording depth in striatum, analyzed by a two-tailed 
unpaired t test.  
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Preface to Chapter Five  
In the previous chapters, I have demonstrated the capabilities of microelectrode 
arrays (MEAs) to detect disruptions in extracellular glutamate in experimental models of 
traumatic brain injury (TBI). Current, neurocritical care for severe traumatic brain injury 
patients uses a multitude of neuromonitoring devices to identify secondary insults, which 
are difficult to detect. We hypothesize that enzyme-based microelectrode arrays (MEAs) 
can provide insight into the pathophysiological mechanisms of TBI and detect potential 
biomarkers to guide the care and management of TBI patients. The purpose of this study 
was to examine the translational potential and capabilities of enzyme-based 
microelectrode arrays (MEAs) as a novel neuromonitoring device for clinical TBI 
research. 
 
Chapter Five: Development of a novel neuromonitor for clinical TBI 
research: enzyme-based microelectrode arrays for real-time in vivo 
detection of neurochemicals  
 
 
Abstract 
Modern neurocritical care management uses a host of monitoring techniques to 
identify secondary insults and guide subsequent therapeutic interventions in an attempt 
to minimize the resulting secondary brain injury in severe TBI survivors. However, the 
onset and extent of secondary brain injury have been difficult to detect. We hypothesize 
that enzyme-based microelectrode arrays (MEAs) can provide insight into the 
pathophysiological mechanisms of TBI and detect potential biomarkers to guide the care 
and management of TBI patients. The purpose of this study was to examine the 
translational potential and capabilities of enzyme-based microelectrode arrays (MEAs) 
as a novel neuromonitoring device for clinical TBI research. MEAs can continuously 
measure extracellular glutamate during the initial 72 hours after implantation, which is 
the temporal window for disruptions in extracellular glutamate previously detected in TBI 
survivors. Second, selective coatings applied to the MEAs allow for simultaneous 
detection of multiple neurochemicals of interest on a single device, such as 
simultaneous detection of glutamate, lactate, pyruvate, and glucose. Molecules that 
have been previously identified as potential biomarkers in clinical microdialysis studies. 
Lastly, we were able to transfer a similar methodology of the MEAs onto an already 
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FDA-approved device, the AD-TECH® Epilepsy/LTM macro-micro depth electrode, for 
selective measures of extracellular glutamate both in vitro and in vivo.  
Introduction 
Current management strategies for traumatic brain injury (TBI) survivors are 
directed towards providing an optimal physiological environment in order to minimize 
secondary brain injury and maximize the body's own regenerative processes. Modern 
neurocritical care management uses a host of monitoring techniques to identify 
secondary insults and guide subsequent therapeutic interventions in an attempt to 
minimize the resulting secondary brain injury that occurs in severe TBI survivors (Tisdall 
and  Smith 2007). However, the onset and extent of secondary brain injury have been 
difficult to detect. A multitude of  invasive neuromonitoring techniques are currently being 
used in the intensive care unit to detect disruptions in intracranial pressure (ICP), 
cerebral perfusion pressure (CPP), cerebral blood flow (CBF), brain tissue oxygen 
tension (PbtO2),  brain temperature, markers of cerebral cellular metabolism such as 
glucose, lactate, pyruvate, glutamate, and glycerol, and intracranial 
electroencephalography (Kirkpatrick, et al. 1996, Patel, et al. 2002, Stuart, et al. 2010).  
However, to date, only ICP monitoring is the standard of care for management of severe 
TBI patients (The Brain Trauma Foundation, 2000). Other than ICP monitoring, no 
consensus exists regarding the selection of neuromonitoring devices for specific patient 
groups, the placement of devices in relation to injured brain tissue, or many of the 
technical aspects of inserting the devices. At present, there is a major controversy in 
whether the use of neuromonitoring devices leads to improved functional outcomes in 
severe TBI patients (Stuart, et al. 2010).  
The overall goals of neuromonitoring in TBI patients is to provide insight into the 
pathophysiological processes of secondary brain injury, identify novel therapeutic 
targets, and reliably detect a biomarker to aid in the diagnosis of TBI severity,  guide 
medical care, predict functional outcomes, and test the efficacy of therapeutics. While 
under development, microdialysis, a method for detecting neurochemical changes in the 
extracellular fluid of the central nervous system, exhibited tremendous potential as a 
novel tool  to uncover the pathophysiological processes of secondary brain and possibly 
detect a biomarker for TBI (Hillered, et al. 1990). Microdialysis involves the implantation 
of a probe, a semi-permeable membrane, that when perfused with a physiological 
solution allows diffusion of small molecules into the probe to be collected and analyzed. 
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Cerebral microdialysis has been used clinically for the past 20 years detecting 
disruptions in the extracellular concentrations of neurochemicals involved in TBI 
pathophysiology (Hillered, et al. 1990, Hillered, et al. 2005, Goodman and  Robertson 
2009). 
Microdialysis has been widely used clinically, primarily due to its ability to detect 
disruptions in the bioenergetics and metabolism of the central nervous system in severe 
TBI patients that includes disruptions in lactate, pyruvate, and glucose (Persson, et al. 
1996, Goodman, et al. 1999, Sarrafzadeh, et al. 2000, Vespa, et al. 2005, Wang, et al. 
2007, Carpenter, et al. 2008, Marcoux, et al. 2008, Meierhans, et al. 2010, Zetterling, et 
al. 2010, De Fazio, et al. 2011, Hejcl, et al. 2011, Nelson, et al. 2011, Timofeev, et al. 
2011a, Yokobori, et al. 2011, Dizdarevic, et al. 2012, Oddo, et al. 2012). In addition, 
microdialysis has detected increases in the excitatory neurotransmitter, glutamate,  
especially in times of ischemia and energy failure (Persson and  Hillered 1992, Bullock, 
et al. 1995, Bullock, et al. 1998, Koura, et al. 1998, Vespa, et al. 1998, Yamamoto, et al. 
1999, Reinert, et al. 2000, Sarrafzadeh, et al. 2000, Hutchinson, et al. 2002, Hlatky, et 
al. 2004, Goodman and  Robertson 2009, Chamoun, et al. 2010, Lakshmanan, et al. 
2010, Timofeev, et al. 2011a). Although microdialysis provides insight into the 
pathophysiological processes of TBI and the corresponding neurochemical changes 
associated with secondary brain injury, microdialysis has failed to reliably detect a 
biomarker that could be used to guide the treatment and management of severe TBI 
patients. The inability of microdialysis to reliably detect a biomarker for TBI may be due 
to inherent methodological limitations of the technique. First, the large sampling area of 
the microdialysis probe (10 mm) and extensive damage surrounding the probe from 
implantation of the device limits the ability of microdialysis to sample extracellular 
neurochemicals that correspond to concentrations near the synapses (Borland, et al. 
2005, Jaquins-Gerstl and  Michael 2009). Second, the temporal resolution of 
microdialysis (1-20 min) is inadequate to sample the fast dynamics of neurochemical 
release and clearance that occurs on the order of milliseconds that likely results in the 
loss of relevant and critical information encoded in the regulation of the neurochemicals 
(Diamond 2005). Lastly, collecting and analyzing the microdialysate for the 
neurochemicals of interest delays examination of the data, thus limiting the usefulness of 
microdialysis in guiding the management and treatment of TBI patients at the bedside. 
Recently developed enzyme-based MEAs have improved upon some of the 
methodological limitations of microdialysis for clinical monitoring of extracellular 
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neurochemicals. The improved spatial resolution (micrometers) and limited damage to 
the surrounding central nervous system during implantation of the device permits 
detection of neurochemicals from synaptic sources (Day, et al. 2006, Rutherford, et al. 
2007, Hascup, et al. 2008, Hinzman, et al. 2012). Since MEAs use electrochemical 
methods, data can be collected on a sub-second time scale allowing the detection of 
dynamic changes in neurochemicals. In addition, electrochemical detection allows data 
to be collected in real-time and displayed bedside, permitting management and 
treatment decisions to be based on neurochemical data. We hypothesize that enzyme-
based microelectrode arrays (MEAs) can provide insight into the pathophysiological 
mechanisms of TBI and detect potential biomarkers to guide the care and management 
of TBI patients. The purpose of this study was to examine the translational potential and 
capabilities of enzyme-based MEAs as a novel neuromonitoring device for clinical TBI 
research. 
 
Materials and Methods 
 
Animals 
Male Sprague-Dawley rats were used for all experiments. The animals were 
housed in a 12 h light/dark cycle with food and water ad libitum according to the 
Association for Assessment and Accreditation of Laboratory Animal Care International. 
Animals were acclimated to their environment for at least 1 week before any 
experiments. After surgery, animals were monitored daily for post-operative care. Animal 
care was approved by the University of Kentucky Institutional Animal Care and Use 
Committee. 
 
Continuous recordings of extracellular glutamate for 72 hours in awake 
animals 
Ceramic-based MEAs, consisting of four platinum recording sites (15 x 333 µm) 
arranged in dual pairs, were prepared and selected for in vivo recordings (Burmeister, et 
al. 2002, Day, et al. 2006). MEAs were prepared and coated for glutamate measures 
similar to previous work with one modification (Burmeister and  Gerhardt 2001, 
Burmeister, et al. 2002, Rutherford, et al. 2007, Hinzman, et al. 2010). On the sentinel 
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recording sites, inactivated glutamate-oxidase was used using the same procedure and 
concentrations as the active glutamate-oxidase. Glutamate-oxidase was inactivated by 
autoclaving ~1.0 µL aliquot of active enzyme. Inactivated glutamate-oxidase was used to 
ensure similar diffusion layers on all recording sites. The two different coatings allowed 
the use of a self-referencing technique, in which the background current of the sentinel 
sites can be subtracted from the current of the glutamate-oxidase sites, thereby 
producing a more selective glutamate measure (Burmeister and  Gerhardt 2001, 
Burmeister, et al. 2002). MEA pedestals were fabricated and constructed for chronic 
glutamate measures similar to previous studies (Rutherford, et al. 2007). 
Before implantation of the MEA pedestal, MEAs were calibrated to test the 
capability of the MEA to measure glutamate and generate a standard curve for the 
conversion of current to glutamate concentration (Hinzman, et al. 2010). Before 
implanting the MEA pedestal, rats underwent a sham injury (Lifshitz 2008, Hinzman, et 
al. 2010, Thomas, et al. 2011). Upon completion of the sham surgery, animals were 
implanted with the MEA pedestal (Rutherford, et al. 2007). MEAs were stereotaxically 
placed in the striatum (AP: +1.0, ML: + 2.5, DV: -4.0). Animals were then placed in the 
recording chamber, 21 x 11 inch plexiglass rectangle, and connected to the FAST-16 
mkII system via hammerhead-type pre-amplifier.  Data was collected at a frequency of 4 
Hz. Animals were provided with food and water ad libitum and remained on their 12 hour 
light/dark cycle.  
Amperometric data were analyzed using custom MATLAB® - based software. 
Extracellular glutamate was calculated using the self-referencing method (Burmeister 
and  Gerhardt 2001, Burmeister, et al. 2002). Data were filtered using a fourier low pass 
filter (0.14) and wavelet low pass filter (3). Extracellular glutamate levels were averaged 
per hour.  
 
Multiple Analyte Calibrations 
MEAs were prepared and coated for the analyte of interest (Burmeister, et al. 
2004) with one modification. Polyurethane was coated by hand onto selected sites 
instead of dipping all sites into polyurethane. Polyurethane was only coated only on the 
platinum recording sites coated with lactate-oxidase and pyruvate-oxidase. Calibrations 
were conducted to test the capability of the MEA to selectively measure the analyte of 
interest. The parameters tested were limit of detection (three times the standard 
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deviation of the baseline noise), sensitivity to the analyte (slope), and the linear increase 
in current due to additions of the analyte (R2).  Constant potential amperometry was 
performed with the MEAs using the FAST-16 mkII system. A potential of +0.7 V versus 
an Ag/AgCl reference was applied to oxidize the reporter molecule, H2O2. The resulting 
current was amplified and digitized by the FAST-16 mkII system. 
 
Modification of FDA-approved device (AD-TECH® Epilepsy/LTM macro-
micro depth electrode) for in vivo detection of glutamate 
AD-TECH® Epilepsy/LTM macro-micro depth electrodes were provided by AD-
TECH® (AD-TECH Medical Instruments, Racine, WI). Probes were prepared and coated 
for glutamate measures (Hinzman, et al. 2010) with minor modifications. A 10 µL 
solution of 2% bovine serum albumin (BSA), 0.25% glutaraldehyde, and 1% glutamate-
oxidase was prepared. Using a dissecting microscope, a microsyringe was used to 
manually apply a small drop (~0.1µL) of the glutamate-oxidase solution onto the micro-
depth electrodes. The increased percentage of BSA and glutaraldehyde compared to 
methods described in Chapters 2, 3, and 4 was used to aid in the adherence of the 
coatings onto the micro-depth electrode.  Multiple coats were applied to the micro-depth 
electrodes until the whole electrode was encapsulated. The same procedure was used 
to coat sentinel sites, micro-depth electrodes coated with a solution containing 2 % BSA 
and 0.25% glutaraldehyde. After coating, the probes were cured for at least 48 hours in 
a low humidity environment. The coated probes were connected to the FAST-16 mk II 
system and the micro-depth electrodes were placed in a 5 mM mPD solution. 
Electroplating software was used to apply a potential as a triangular wave with an offset 
of -0.5V, peak to peak amplitude equal to 0.25V, at a frequency of 0.05 Hz, for a period 
of 25 minutes to electroplate the mPD on the micro-depth electrodes. Probes were cured 
for an additional 24 hours in a low humidity environment before use. 
Calibrations were conducted to test the capability of the probe to measure 
glutamate and generate a standard curve for the conversion of current to glutamate 
concentration. The AD-TECH® Epilepsy/LTM macro-micro depth electrode was placed in 
a continuously stirred 40 ml solution of 0.05 M phosphate buffered saline (PBS) 
maintained at 37 ºC with a re-circulating water bath. The probes were exposed to final 
concentrations of 250 µM AA, 20, 40, 60 µM glutamate, 2 µM DA, and 8.8 µM H2O2. 
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Parameters tested were limit of detection (LOD), selectivity for glutamate over ascorbic 
acid, slope of the electrode (sensitivity), and linearity of the glutamate response (R2). 
Animals were anesthetized with isoflurane and prepared for in vivo 
electrochemical recordings (Burmeister, et al. 2002, Pomerleau, et al. 2003, Day, et al. 
2006). Briefly, animals were placed in a stereotaxic frame and body temperature was 
maintained at 37 °C with a water pad connected to a re-circulating water bath. A 
craniotomy was performed to provide access to the striatum. A Ag/AgCl reference wire 
was implanted into the lateral parietal cortex in the opposite hemisphere from the 
recording areas. The AD-TECH® Epilepsy/LTM macro-micro depth electrode was 
lowered into the brain using a microdrive. All recordings were performed at a frequency 
of 4 Hz using constant potential amperometry. Glutamate was locally applied into the 
striatum using a 30 gauge Hamilton needle. While the animal was under isoflurane 
anesthesia, urethane was administered (1.25 g/kg i.p.).                                
Amperometric data were analyzed using custom MATLAB® - based software. 
Extracellular glutamate was calculated using the self-referencing method (Burmeister 
and  Gerhardt 2001, Burmeister, et al. 2002). For local application of glutamate, data 
were filtered using a fourier low pass filter (0.14). For analysis of the decrease in 
extracellular glutamate from injection of urethane, data were filtered with a fourier low 
pass filter (0.14) and with a 10 sec boxcar average. The data collected five minutes prior 
to urethane injection and minutes 5-10 after the urethane injection were compared. 
 
Results 
 
 MEAs can continuously measure extracellular glutamate for the inital 72 
hours after implanation  
Disruptions in extracellular glutamate have been detected in traumatic brain 
injury survivors using microdialysis, with a vast majority of these disruptions being 
detected within the first 72 hours of implantation of the microdialysis probe (Persson and  
Hillered 1992, Bullock, et al. 1995, Bullock, et al. 1998, Koura, et al. 1998, Vespa, et al. 
1998, Yamamoto, et al. 1999, Reinert, et al. 2000, Sarrafzadeh, et al. 2000, Hutchinson, 
et al. 2002, Hlatky, et al. 2004, Chamoun, et al. 2010, Lakshmanan, et al. 2010, 
Timofeev, et al. 2011a). To test the ability of MEAs to continuously record extracellular 
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glutamate for the initial 72 hours after implantation, we implanted rats with a MEA and 
recorded extracellular glutamate levels continuously in the rats for the initial 72 hours 
after implantation (Fig 5.1A).  
In the first animal, we recorded extracellular glutamate levels continuously for 74 
hours. In the first hour, extracellular glutamate averaged 0.4 µM with a gradual rise in 
extracellular glutamate over the next 10 hours reaching a maximum of 10.5 µM. Then, 
extracellular glutamate levels slowly fell over the next 30 hours where the extracellular 
glutamate concentration remained stable around ~1.0 µM for the remainder of the 
recording (Fig 5.1B). In the second animal, we record extracellular glutamate levels 
continuously for 75 hours. Similar to the first animal, there was an initial rise in 
extracellular glutamate rising from 4.5 µM in the first hour to 28.2 µM thirteen hours later. 
Unlike the first animal, extracellular glutamate exhibited a diurnal rhythm with sharp 
increases in extracellular glutamate levels at the start of the second and third dark 
cycles. The hour prior to the start of the second dark cycle, extracellular glutamate 
averaged 14.4 µM sharply rising to a maximum of 22.8 µM six hours later. The hour prior 
to the start of the third dark cycle, extracellular glutamate averaged 12.4 µM sharply 
rising to a maximum of 17.1 µM three hours later. In the second animal, extracellular 
glutamate exhibited a potential diurnal rhythm but did not reach a stable baseline during 
the 75 hours of recording (Fig 5.1C). Thus, MEAs can continuously record extracellular 
glutamate for at least the initial 72 hours after implantation.  
 
Detection of multiple analytes of interest using a single MEA (glutamate, 
lactate, pyruvate, or glucose) 
Microdialysis studies in TBI survivors have identified certain compounds that 
could be potential biomarkers for TBI, with extracellular levels of these compounds 
correlating with injury severity and functional outcomes. The four molecules that have 
been consistently disrupted in TBI survivors are glutamate (Persson and  Hillered 1992, 
Bullock, et al. 1995, Bullock, et al. 1998, Koura, et al. 1998, Vespa, et al. 1998, 
Yamamoto, et al. 1999, Reinert, et al. 2000, Sarrafzadeh, et al. 2000, Hutchinson, et al. 
2002, Hlatky, et al. 2004, Chamoun, et al. 2010, Lakshmanan, et al. 2010, Timofeev, et 
al. 2011a), lactate and pyruvate (Persson, et al. 1996, Goodman, et al. 1999, 
Sarrafzadeh, et al. 2000, Vespa, et al. 2005, Wang, et al. 2007, Carpenter, et al. 2008, 
Marcoux, et al. 2008, Meierhans, et al. 2010, Zetterling, et al. 2010, De Fazio, et al. 
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2011, Hejcl, et al. 2011, Nelson, et al. 2011, Timofeev, et al. 2011a, Yokobori, et al. 
2011, Dizdarevic, et al. 2012, Oddo, et al. 2012), and glucose (Caspari, et al. 1992, 
Persson, et al. 1996, Alessandri, et al. 2000, Vespa, et al. 2003, Meierhans, et al. 2010, 
Timofeev, et al. 2011a, Timofeev, et al. 2011b, Yokobori, et al. 2011, Dizdarevic, et al. 
2012).  
Previous work in our laboratory has shown that MEAs can detect glutamate, 
lactate, and glucose (Burmeister, et al. 2004). However, the ability of MEAs to detect 
multiple analytes on a single MEA was unknown. The purpose of this experiment was to 
examine the ability of a single MEA to detect multiple compounds of interest. A major 
obstacle for detection of multiple compounds on a single device is the potential vast 
concentration differences between the compounds. Extracellular concentrations of 
glutamate and pyruvate are in the micromolar range. While extracellular concentrations 
of lactate and glucose are in the millimolar range. Another obstacle for the detection of 
lactate and glucose is the saturation of their corresponding oxidase enzymes. These 
enzymes saturate at ~1 mM limiting the ability of the MEAs to detect physiological 
concentrations. To overcome saturation of the enzymes polyurethane coatings were 
developed to produce a diffusion barrier preventing saturation of the enzymes and 
shifting the detectable range into the millimolar range.  
The first MEA was configured for the detection of glutamate and lactate. The in 
vitro calibration demonstrated the ability of the MEA to simultaneously measure 
glutamate and lactate (Fig 5.2A). Additions of 20 µM glutamate produced a step-wise 
increase in current on the platinum recording site coated with glutamate-oxidase with no 
response on the recording sites coated with lactate-oxidase. For the glutamate-oxidase 
recording site, the sensitivity to glutamate was 7.3 pA/µM (slope), detection limit of 1.0 
µM (LOD), and linearity of response equal to 0.99 (R2). Additions of 2 mM lactate 
produced a robust step-wise increase in current on the recording site coated with 
lactate-oxidase with no response on the glutamate-oxidase site despite the large 
increase in current corresponding to the high concentrations of lactate. For the lactate-
oxidase recording site, the sensitivity to lactate was 0.3 pA/µM (slope), detection limit of 
20 µM (LOD), and linearity of response equal to 0.99 (R2). Using the polyurethane 
coating, we were able to measure up to 10 mM lactate with a linear response.  
The second MEA was configured for the detection of glutamate and pyruvate. 
The in vitro calibration demonstrated the ability of the MEA to simultaneously measure 
glutamate and pyruvate (Fig 5.2B). Additions of 20 µM and 100 µM pyruvate produced a 
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corresponding step-wise increase in current on the recording site coated with pyruvate-
oxidase with minimal response on the glutamate-oxidase site during additions of the 
pyruvate. For the pyruvate-oxidase recording site, the sensitivity to pyruvate was 1 
pA/µM (slope), detection limit of 0.6 µM (LOD), and linearity of response equal to 0.98 
(R2) up to 500 µM. Additions of 20 µM glutamate produced a step-wise increase in 
current on the platinum recording site coated with glutamate-oxidase with no response 
on the recording site coated with pyruvate-oxidase. For the glutamate-oxidase recording 
site, the sensitivity to glutamate was 11 pA/µM (slope), detection limit of 0.1 µM (LOD), 
and linearity of response equal to 0.99 (R2).  
The third MEA was configured for the detection of glucose and lactate. 
Polyurethane was coated on the recording sites coated with glucose-oxidase and 
lactate-oxidase. The in vitro calibration demonstrated the ability of the MEA to 
simultaneously measure glucose and lactate (Fig 5.2C). Additions of 4 mM glucose 
produced a robust step-wise increase in current on the platinum recording site coated 
with glucose-oxidase with no response on the recording sites coated with lactate-
oxidase. For the glucose-oxidase recording site, the sensitivity to glucose was 0.18 
pA/µM (slope), detection limit of 12 µM (LOD), and linearity of response equal to 0.95 
(R2). Additions of 4 mM lactate produced a step-wise increase in current on the 
recording sites coated with lactate-oxidase with no response on the glucose-oxidase 
site. For the lactate-oxidase recording site, the sensitivity to lactate was 0.022 pA/µM 
(slope), detection limit of 64 µM (LOD), and linearity of response equal to 0.99 (R2). 
Using the polyurethane coating, we were able to measure up to 20 mM glucose and 8 
mM lactate concentrations with a reasonable linear response. Thus, with the use of 
polyurethane and selective enzyme coatings, MEAs exhibit the ability to detect multiple 
analytes (glutamate, pyruvate, lactate, and glucose) on a single device. MEA coatings 
and calibrations were performed in collaboration with Jason Burmiester.  
 
Modification of FDA approved device (AD-TECH® Epilepsy/LTM macro-
micro depth electrode) for in vivo detection of glutamate 
The AD-TECH® Epilepsy/LTM macro-micro depth electrode provides up to 16 
micro-electrodes (38 µM platinum wire) that could be coated similar to the MEAs for 
detection of neurochemicals. The AD-TECH® Epilepsy/LTM macro-micro depth electrode 
has four macro-depth electrodes with multiple rows of four micro-depth electrodes 
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residing above the macro-depth electrodes (Fig 5.3A). Some of the micro-depth 
electrodes were coated with glutamate-oxidase for the detection of glutamate while other 
micro-depth electrodes were coated with an inactive protein matrix (sentinel sites) to 
allow for self-referencing (see methods for details). Using similar coating procedures, we 
were able to adhere enzyme onto the micro-depth electrodes (Fig 5.3B). The in vitro 
calibration demonstrated the ability of the AD-TECH® Epilepsy/LTM macro-micro depth 
electrode to selectively measure glutamate (Fig 5.3C). Addition of a major interferent 
(250 µM ascorbic acid) produced little response on the glutamate-oxidase and sentinel 
micro-depth electrodes. Additions of 20 µM glutamate produced a step-wise increase in 
current on the micro-depth electrodes coated with glutamate-oxidase with minimal 
response on the sentinel micro-depth electrode. Addition of 8.8 µM H2O2 produced an 
increase in current on both the glutamate-oxidase and sentinel micro-depth electrodes. 
For the micro-depth electrode coated with glutamate-oxidase, the sensitivity to glutamate 
was 15 pA/µM (slope), detection limit of 0.9 µM (LOD), selectivity for glutamate over 
ascorbic acid (91:1), and linearity of response equal to 0.99 (R2). Thus, we were able to 
modify an AD-TECH® Epilepsy/LTM macro-micro depth electrode to selectively measure 
glutamate in vitro.  
Next, we examined the ability of the AD-TECH® Epilepsy/LTM macro-micro depth 
electrode to measure extracellular glutamate in vivo.  The AD-TECH® Epilepsy/LTM 
macro-micro depth electrode was implanted into the striatum of a rat under isoflurane 
anesthesia (Fig 5.4A).  Local application of 500 µM glutamate into the rat striatum 
produced a robust and rapid increase in extracellular glutamate that rapidly returned to 
baseline (Fig 5.4 B). Prior to injection of glutamate, the baseline value of glutamate was 
9.0µM. Local application of 500 µM glutamate produced a glutamate signal with a 
maximum amplitude of 109.3 µM that decayed back to baseline levels through glutamate 
uptake and diffusion from the probe. The time for the signal to decay 80 % (T80) was 
11.75 s, with an uptake rate of 9.58 µM/s. In a second experiment, we examined if we 
could modulate extracellular glutamate levels. Injection of urethane has been shown to 
reduce extracellular glutamate levels in awake rats (Rutherford, et al. 2007). While the 
rat was under isoflurane anesthesia, 1.25 mg/kg of urethane was injected i.p. Under 
isoflurane anesthesia, extracellular glutamate levels averaged 1.8 µM, five minutes after 
injection of urethane extracellular glutamate levels decreased by ~75% to 0.4 µM (five 
minute average of extracellular glutamate) (Fig 5.5C). Thus, a modified AD-TECH® 
Epilepsy/LTM macro-micro depth electrode can measure extracellular glutamate in vivo.  
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Discussion 
The purpose of this study was to examine the translational potential of MEAs as 
a novel neuromonitoring device for clinical TBI research. Here, we report MEAs exhibit 
the properties and capabilities to be a useful tool for clinical TBI research. First, MEAs 
can continuously measure extracellular glutamate for the initial 72 hours after 
implantation, which is the temporal window for disruptions in extracellular glutamate in 
TBI survivors. Second, MEAs can detect multiple potential biomarkers (glutamate, 
lactate, pyruvate, or glucose) on a single device, molecules that have been previously 
shown to correlate with injury severity and functional outcomes. Lastly, we were able to 
transfer a similar methodology of the MEAs onto an already FDA-approved device, AD-
TECH® Epilepsy/LTM macro-micro depth electrode, for selective measures of 
extracellular glutamate both in vitro and in vivo.  
The use of an enzyme-based system with constant potential amperometry has 
certain methodological advantages over microdialysis, currently the only in vivo method 
to detect dynamic extracellular changes in neurochemicals clinically. Since constant 
potential amperometry measures the current from the oxidation of H2O2 generated from 
specific oxidase enzymes, data are collected at a sub-second scale with real-time data 
readout at the bedside possible. Although improvements are being made for online 
analysis of microdialysis samples, most studies require collection and analysis of the 
microdialysate to obtain neurochemical values. Recent methodological advancements 
with bedside analyzers such as the CMA ISCUSflex (CMA/Microdialysis, Sweden) permits 
analysis, monitoring, and time trend display of neurochemicals that interfaces with 
commonly used intensive care unit systems. However, this approach permits only 
analysis of glucose, pyruvate, lactate, glycerol and glutamate (Goodman and  Robertson 
2009). Also, the improved spatial resolution of MEAs and limited damage to the 
surrounding tissue allows sampling of neurochemicals from the synaptic pool (Day, et al. 
2006, Rutherford, et al. 2007, Hascup, et al. 2008, Hinzman, et al. 2012). In contrast, the 
large sampling area of the microdialysis membrane (10 mm length) and extensive 
damage from implantation of the microdialysis probe, which limits the ability of 
microdialysis to sample neurochemicals from the synaptic pool (Borland, et al. 2005, 
Jaquins-Gerstl and  Michael 2009). Furthermore, the low temporal resolution of 
microdialysis (1-20 min) is inadequate to sample the fast dynamics of neurochemical 
release and clearance that occurs on the order of milliseconds to seconds (Diamond 
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2005). Thus, due to these methodological improvements MEAs exhibit tremendous 
potential as a clinical research tool for TBI.  
Our laboratory has developed multiple MEA prototypes for clinical use. The first 
prototype, Spencer-Gerhardt (SG1), embeds a S2-style MEA onto the surface of a FDA-
approved device (Fig 5.5A). Embedding the MEA on the surface of an AD-TECH® 
Spencer® probe provides certain advantages for clinical use. The MEAs would be able to 
gain access to the central nervous system to detect extracellular neurochemicals without 
the need for additional surgeries or implantations of devices. Also, embedding the MEA 
on a currently used device such as the AD-TECH® Spencer® probe would reduce the 
need for additional training on handling or implanting the device by neurosurgeons. 
However, permanently embedding the device produces certain disadvantages such as 
the inability to remove the MEA independently of the AD-TECH® Spencer® probe.  Also, 
placement of the MEA into the central nervous system will be limited to placement of the 
AD-TECH® Spencer® probe. The second prototype, Spencer-Gerhardt (SG2), was 
developed as an independent device. The SG2 has a S2-style MEA placed on the tip of 
a long thin polyimide tubing (Fig 5.5B). This prototype allows the MEA to be implanted 
independently and can be placed in the brain region of interest. Since the device is 
independent, additional surgery and procedures will be required for implantation. 
However, this will allow for independent removal of the device. Recent designs of MEAs 
provide better configurations for the detection of multiple analytes. The DS-PR-8 is a 
double sided MEA with 16 platinum recording sites, eight on each side arranged in pairs 
(Fig 5.3C). The configuration of the DS-PR-8 could potentially allow for the simultaneous 
detection of glutamate, lactate, pyruvate, and glucose on a single device. Further work is 
needed to examine the capability of the DS-PR-8 to simultaneously measure all four 
analytes of interest.  Lastly, a third clinical prototype is in development, which combines 
features of the SG1 and SG2. The third generation prototype would consist of an FDA-
approved device, such as the AD-TECH® Epilepsy/LTM Behnke fried depth electrode 
that has a central open lumen with an opening at the tip allowing a MEA to be inserted 
through the middle of the device and extended out of the tip and into the tissue. This 
strategy would reduce the need for additional surgeries and implantations while retaining 
the ability to remove the device independently. Ongoing work is proceeding to evaluate 
and improve clinical designs for translation of MEA technology into the clinic. 
  Extracellular glutamate recordings in awake animals for the initial 72 hours after 
implantation revealed a substantial initial increase in extracellular glutamate in the first 
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10-13 hours after implantation. The inflammatory response from implantation of 
electrodes into the central nervous systems activates microglia and signals migration of 
microglia to the injury site, which secrete reactive oxygen species, inflammatory 
cytokines, and release extracellular glutamate (Turner, et al. 1999, Block and  Hong 
2005, Polikov, et al. 2005, Block, et al. 2007, McConnell, et al. 2007, Rutherford, et al. 
2007). However, these responses are thought to occur over days and weeks after 
implantation of the device (Turner, et al. 1999). Initial implantation of the device 
damages multiple structures including capillaries, extracellular matrix, cells, and permits 
blood-borne macrophage entry into the CNS (Polikov, et al. 2005). The initial damage 
and subsequent cellular responses may be responsible for the initial increase in 
extracellular glutamate during the initial 10-13 hours after injury. A likely source of 
extracellular glutamate is from activated microglia. Also, the cytokine release from the 
initial damage during implantation may produce cellular swelling and edema, shrinking 
the extracellular space; thereby, increasing the extracellular glutamate concentration. 
Future work, should examine if pre-treatment with an anti-inflammatory, such as 
Rimadyl® (carprofen), could reduce or prevent the initial rise in extracellular glutamate.  
The ability of the MEAs to simultaneously detect multiple analytes is a significant 
milestone for MEA technology. Detection of only a single compound of interest was a 
major disadvantage of MEAs compared to microdialysis, where multiple compounds 
could be detected and analyzed. Unexpectedly, the MEAs configured for detection of 
multiple analytes exhibited a similar performance for the detection of the compounds of 
interest compared to MEAs configured to detect only a single analyte (Burmeister, et al. 
2002, Burmeister, et al. 2004, Burmeister, et al. 2005, Hinzman, et al. 2010). Current 
work on newer configurations of MEAs, such as the DS-PR-8, will allow simultaneous 
detection of multiple compounds of interest. The newer designs of the MEAs with 
platinum recordings sites on the front and the back of the ceramic shank will allow the 
coating of oxidase enzyme on one side and the corresponding sentinel site on the other 
side. The front/back design should prevent crosstalk where peroxide generated from the 
oxidase enzyme diffuses to the sentinel site providing a false signal. Also, the eight pairs 
of platinum recording sites arranged vertically on the ceramic shank will allow the bottom 
recording sites to be “dip” coated with polyurethane, which is easier and more 
reproducible than the hand coating of polyurethane onto the individual platinum 
recording sites, which is necessary for the detection of lactate and glucose.  Further 
work is needed to optimize configurations and a coating on the newer electrode designs 
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for the simultaneous detection of glutamate, lactate, pyruvate, and glucose on a single 
device.  
An easier path into the clinic may be modifying an already FDA-approved device 
for detection of the molecules of interest. In this report, we were able to modify an AD-
TECH® Epilepsy/LTM macro-micro depth electrode to measure extracellular glutamate 
both in vitro and in vivo. Using a similar methodology to the MEAs, we were able to coat 
the microelectrode with glutamate-oxidase and an inactive protein matrix to allow for 
self-referencing. The modified AD-TECH® Epilepsy/LTM macro-micro depth electrode 
was able to selectively measure glutamate with similar selectivity, limit of detection, and 
linearity compared to MEAs (Burmeister, et al. 2002, Hinzman, et al. 2010). However, 
the sensitivity to glutamate (slope) was substantially lower on the AD-TECH® 
Epilepsy/LTM macro-micro depth electrode compared to MEAs. Increasing the 
sensitivity of the probe could be achieved by increasing the active surface area of the 
micro-depth electrodes. One option is to increase the diameter of the platinum wire, such 
as the AD-TECH® Epilepsy/LTM macro-micro depth electrode (MM14A-SP05X-000) with 
50 µm platinum wires for the micro-depth electrodes. Another option is pooling multiple 
micro-depth electrodes into a single channel; however, this option would increase the 
background current and could reduce the spatial ability of the channel to detect 
glutamate, especially if glutamate release is localized to a single micro-depth electrode. 
Another way to improve the performance is to move the preamplifier closer to the 
Epilepsy/LTM macro-micro depth electrode, which should reduce the noise and improve 
signal detection of the probes. Future work should examine these improvements and 
further evaluate the ability of FDA-approved devices for the detection of neurochemicals. 
In conclusion, MEAs have tremendous potential as a clinical tool to help 
understand the pathophysiology of TBI and possibly detect a reliable biomarker(s) to aid 
in the diagnosis of TBI severity, guide management and care of the patient, predict 
functional outcomes, and test the efficacy of therapeutics. TBI offers a unique platform 
for translation of this technology into the clinic due to the large number of devices 
already implanted into the central nervous system of TBI patients. Future work should 
determine what enzyme/exclusion coatings would be permitted for use in the clinic, 
develop a final clinical prototype, ensure performance of sterilized probes both in vitro 
and in vivo, and examine damage to the central nervous system from implantation of the 
device compared to other currently used devices, preferably in larger animal models. 
Advancement of MEAs or MEA technology into the clinic may provide a better 
 96 
understanding of TBI pathophysiology leading to the development of novel drugs, and/or 
provide an improved tool to test the efficacy of therapeutics, which could lead to 
improved outcomes in TBI survivors. 
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Chapter Five: Figures  
                                                                                       
 
Figure 5.1 MEAs can continuously measure extracellular glutamate for the inital 72 
hours after implanation  
 
(A) Rat in the recording chamber was implanted with a MEA pedestal connected to the 
FAST-16 recording system via a hammerhead-type pre-amplifier. (B) Extracellular 
glutamate levels in the rat striatum during the initial 72 hours after implantation, 
open/closed blocks correspond to the day/night cycle. Note the initial rise in extracellular 
glutamate in the first 10-13 hours that subsides over the next 24-36 hours (glutamate 
averaged per hour, n=1). (C) Extracellular glutamate levels in the rat striatum during the 
initial 72 hours after implantation, open/closed blocks correspond to the day/night cycle. 
Note the initial rise in extracellular glutamate in the first 10 hours and subsequent 
increases in extracellular glutamate that correspond with start of the night cycle on the 
second and third nights (glutamate averaged per hour, n=1). 
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Figure 5.2 MEAs can detect multiple analytes of interest on a single device 
(glutamate, lactate, pyruvate, and glucose)  
 
(A) Calibration of a MEA coated with glutamate-oxidase and lactate-oxidase. Four 
additions of 20 µM glutamate (↑) produced a stepwise increase in current on the 
recording site coated with glutamate-oxidase (red). Five additions of 2mM lactate (↑) 
produced a stepwise increase in current on the recording site coated with lactate-
oxidase (green). Note the lack of cross talk between the glutamate-oxidase and lactate-
oxidase sites despite the robust signals and concentration differences between the 
analytes. (B) Calibration of a MEA coated with glutamate-oxidase and pyruvate-oxidase. 
Five additions of 20 µM pyrvuate (small ↑) and three additions of 100 µM pyruvate (large 
↑) produced a proportional stepwise increase in current on the recording site coated with 
pyruvate-oxidase (grey). Five additions of 20 µM glutamate (↑) produced a stepwise 
increase in current on the recording site of the MEA coated with glutamate-oxidase (red). 
(C) Calibration of a MEA coated with glucose-oxidase and lactate-oxidase. Five 
additions of 4 mM glucose (↑) produced an increase in current on the recording site of 
the MEA coated with glucose-oxidase (blue). Two additions of 4mM lactate (↑) produced 
an increase in current on the recording site coated with lactate-oxidase (green). Results 
obtained in collaboration with Jason Burmeister.  
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Figure 5.3 Modification of FDA-approved device AD-TECH® Epilepsy/LTM macro-
micro depth electrode for real-time glutamate measures using constant 
potential amperometry  
 
(A) Picture of AD-TECH® Epilepsy/LTM macro-micro depth electrode. (B) Inset, 
depicting a micro-electrode in between two macro-electrodes that has been coated 
with glutamate-oxidase for detection of glutamate. (C) In vitro calibration measuring 
the change in current on the micro-electrode coated with glutamate-oxidase (red) 
and micro-electrode coated with inactive protein matrix (sentinel, black). Addition of 
an interferent (↑) ascorbic acid produced no change in current on the glutamate-
oxidase or sentinel sites. Three glutamate additions (↑) showed a stepwise increase 
of current on the glutamate-oxidase site with no response on the sentinel site. 
Addition of H2O2 (↑) produced an increase in current on both the glutamate-oxidase 
and sentinel site. 
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Figure 5.4 In vivo detection of extracellular glutamate using modified AD-TECH® 
Epilepsy/LTM macro-micro depth electrode 
 
(A) Picture showing the AD-TECH® Epilepsy/LTM macro-micro depth electrode 
implanted in the striatum of an anesthetized rat. (B) Local application of 500 µM 
glutamate (↑) into the rat striatum produced a robust and rapid increase in extracellular 
glutamate that rapidly returned to baseline. Inset, depicts the change in current from 
local application of 500 µM glutamate on a micro-electrode coated with glutamate-
oxidase and a micro-electrode coated with an inactive protein matrix (sentinel). Note the 
lack of response on the sentinel channel. (C) Extracellular glutamate levels decreased 
after an injection of urethane. While the animal was under isoflurane anesthesia 1.25 
mg/kg of urethane was injected i.p. Under isoflurane anesthesia extracellular glutamate 
levels averaged 1.8 µM, five minutes after injection of urethane extracellular glutamate 
levels decreased by ~75% to 0.4 µM (five minute average of extracellular glutamate). 
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Figure 5.5 MEA prototypes for clinical use  
 
(A,) Picture of Spencer-Gerhardt (SG1) electrode, a modified AD-TECH® Spencer® 
probe with a S2-style MEA embedded on the surface of the probe. Higher magnification 
images show the S2-style MEA embedded on the surface of the AD-TECH® Spencer® 
probe. (D) Picture of second generation of the Spencer-Gerhardt (SG2) electrode with a 
S2-style MEA placed on the tip of a polyimide tubing to allow for implantation into deeper 
brain structures. (E) Double-sided MEA (DS-PR-8) with 16 platinum recording sites, 
eight on each side, to allow for the detection of multiple analytes of interest on a single 
device. Images courtesy Peter Huettl.  
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Chapter Six: Overall Conclusions 
 
In summary, we have detected several disruptions in the regulation of 
extracellular glutamate in the rat striatum two days after a diffuse brain injury. First, we 
detected significant increases in tonic glutamate with tonic glutamate levels correlating 
with the severity of injury. Second, we determined the contribution of pre-synaptic 
calcium channel-dependent neuronal glutamate release to extracellular glutamate was 
significantly decreased in brain-injured animals compared to uninjured animals. Third, 
the amplitude of glutamate released from local stimulation with KCl was significantly 
greater in the striatum of brain-injured animals compared to uninjured animals. Fourth, 
brain-injured animals exhibited slower clearance of extracellular glutamate compared to 
uninjured animals, due primarily to decreases in glutamate uptake. These results are 
depicted in schematic format to highlight the disruptions in the regulation of extracellular 
glutamate in the rat striatum two days after diffuse brain injury (Fig 6.1).   
Although tonic glutamate levels were significantly increased in the dentate gyrus 
and striatum two days after diffuse brain injury, the extracellular concentrations of 
glutamate do not appear to reach excitotoxic levels as a continuous infusion of 1.8 M 
glutamate at 0.5 µL/hr was insufficient to produce a neuropathological lesion (Mangano 
and  Schwarcz 1983). However, the post-traumatic increases in tonic glutamate may 
play a role in a slower, indirect form of excitotoxicity that is mediated by physiological 
concentrations of glutamate and is thought to be involved in chronic neurodegenerative 
disorders such as Parkinson's disease, Huntington's disease, amyotrophic lateral 
sclerosis, and Alzheimer's disease (Albin and  Greenamyre 1992, Beal 1992b). “Slow 
excitotoxicity” involves mitochondrial damage producing an overall reduction in 
intracellular ATP that impairs the ability of the Na+/K+ ATPase to maintain the resting 
membrane potential (Greene and  Greenamyre 1996, Doble 1999). The loss of a stable 
membrane potential leads to cellular depolarization, removal of the magnesium block 
from the NMDA receptor, and opening of voltage-gated calcium channels. With cellular 
depolarization and removal of the magnesium block, the NMDA receptor is more 
susceptible to activation by ambient or even slightly elevated levels of extracellular 
glutamate (Beal 1992a, Greene and  Greenamyre 1996, Doble 1999). Over prolonged 
periods of time, slight increases in the activation of the NMDA receptors can activate the 
same pathophysiological processes of acute excitotoxicity responsible for neuronal 
death (Olney and  de Gubareff 1978, Doble 1999). Slow excitotoxicity may be the 
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pathophysiological mechanism responsible for the increased risk of epilepsy, 
Parkinson’s disease, and  Alzheimer's disease in TBI survivors (Masel and  DeWitt 
2010). Persistent changes in glutamate regulation in the thalamus and somatosensory 
cortex have been detected up to 28 days post-injury, suggesting long-term disruptions in 
glutamate regulation (Thomas, et al. 2011). Further work is needed to determine if 
disruptions in the regulation of extracellular glutamate will hold true for later time points 
or indefinitely, providing further evidence for “slow excitotoxicity” as a chronic 
pathophysiological mechanism of TBI. 
Damage from the mechanical forces of the primary brain injury and resulting 
secondary injury leads to neuronal death and disruption of functional neuronal circuits. 
The plasticity of the central nervous system facilitates re-connections of synapses and 
reformation of neuronal networks (Wieloch and  Nikolich 2006). This plasticity can be 
adaptive, re-establishing functional connections or bypassing the damaged area, 
resulting in normal neurological function; or the plasticity can be maladaptive, forming 
dysfunctional connections and circuits responsible for producing neurological deficits. 
Post-traumatic increases in extracellular glutamate may aide maladaptive plasticity 
forming dysfunctional neuronal connections. Pro-inflammatory cytokines, which are 
released after TBI, alter the composition, trafficking, and distribution of glutamate 
receptors leading to increased expression of receptors on the cell surface (Beattie, et al. 
2010). The increased surface expression of glutamate receptors in combination with 
increased extracellular glutamate levels may lead to activation of receptors under 
ambient conditions. Also, post-traumatic increases in extracellular glutamate could lead 
to the activation of glutamate receptors extrasynaptically or on neighboring synapses, 
disrupting neuronal signalling. Activation of extrasynaptic NMDA receptors alters the 
trafficking, surface expression, and function of NMDA receptors, which can result in 
eliptogenesis (Luhmann, et al. 1995, Frasca, et al. 2011). Further work is needed to 
determine if improved glutamate regulation after a TBI prevents or reduces the 
neurological deficits associated with maladaptive plasticity, such as post-traumatic 
epilepsy or sensory sensitivity observed in animal models (D'Ambrosio, et al. 2004, 
McNamara, et al. 2010, Thomas, et al. 2011).  
Tonic glutamate levels in the striatum of brain-injured rats were insensitive to the 
calcium channel blocker ω-conotoxin compared to uninjured animals, suggesting a 
limited contribution of calcium-dependent vesicular glutamate release to tonic glutamate. 
This could be explained by either a post-traumatic decrease in neuronal glutamate 
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release with a concurrent increase in non-neuronal sources of glutamate, or a post-
traumatic alteration in the mechanism of vesicular glutamate release that is independent 
of calcium entry through the calcium channel. Regardless of the mechanism, our data 
would suggest sodium or calcium channel blockers, may be ineffective in reducing 
extracellular levels of glutamate. Although we did not detect a significant decrease in 
extracellular glutamate from transient activation of mGluR2/3, future studies should 
examine if long-term activation of the glutamate autoreceptors mGluR2/3, which inhibit 
presynaptic glutamate release and increase expression of the glutamate transporters, 
can improve the regulation of extracellular glutamate (Nakanishi 1994, Di Iorio, et al. 
1996, Battaglia, et al. 1997, Allen, et al. 1999, Schoepp 2001, Zhou, et al. 2006).  
Glutamate clearance was significantly slower in the striatum of brain-injured rats 
compared to uninjured rats, with the decrease in glutamate clearance primarily due to 
decreases in glutamate uptake. Post-traumatic decreases in glutamate uptake are likely 
responsible for the increases in tonic glutamate levels and evoked glutamate release 
detected in the striatum of brain-injured rats. Decreased expression of the glutamate 
transporters (EAATs) has been detected both clinically and in experimental models of 
TBI, suggesting post-traumatic reductions in glutamate uptake plays a pivotal role in the 
pathophysiology of secondary brain injury (Rao, et al. 1998, van Landeghem, et al. 
2001, Yi, et al. 2005, van Landeghem, et al. 2006, Yi and  Hazell 2006). Reduced 
glutamate uptake may lead to increased activation of glutamate receptors and fail to 
contain glutamate release within a single synapse permitting glutamate spillover to 
neighboring synapses. Further work is needed to pinpoint the mechanism responsible 
for decreased glutamate uptake in brain-injured rats; biotinylation of the EAATs could 
examine the surface expression of the receptors and possible oxidative damage to the 
receptors to determine if reduced glutamate uptake is due to lower expression of the 
EAATs and/or a decrease in the function of the EAATs (Trotti, et al. 1998, Nickell, et al. 
2007). 
Since we detected decreases in glutamate uptake in the striatum of brain-injured 
rats, we wanted to examine therapeutic strategies to increase glutamate uptake and 
improve glutamate regulation. At the time, intraperitoneal administration of a beta-lactam 
antibiotic (ceftriaxone) was the only known method to increase the expression of 
glutamate transporters in the rat brain (Rothstein, et al. 2005). Furthermore, 
administration of ceftriaxone was shown to reduce neuronal damage and improve 
behavioral outcomes in a rat model of stroke, providing evidence that increasing 
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glutamate transporters is a viable approach to prevent/reduce excitotoxicity (Chu, et al. 
2006, Chu, et al. 2007). However, this approach was unable to target the expression of 
the glutamate transporters into the brain region of interest, which may disrupt glutamate 
signaling in undesired regions producing similar adverse effects seen with glutamate 
receptor antagonist (Blanke and  VanDongen 2009). The overall goal of our viral studies 
was to identify a novel therapeutic approach that could target the expression of 
glutamate transporters into the brain region of interest to prevent/limit excitotoxicity while 
limiting adverse effects. Using a viral-vector mediated gene delivery approach (AAV-
GLT-1) we were able to increase the expression of functional GLT-1 into the rat striatum. 
Work by our collaborator (Dr. Brandon Harvey) showed that intracerebral infusions of 
AAV-GLT-1 into three cortical sites in the distribution of the right middle cerebral artery 
prior to occlusion, reduced cerebral infarction, improved functional recovery, reduced 
ischemia-induced glutamate overflow, and reduced tissue damage (Harvey, et al. 2011). 
This work further validates the theory that increasing expression of glutamate 
transporters can improve glutamate regulation, reduce excitotoxicity, and improve 
outcomes in a model of excitotoxicity. With further development, viral-vector mediated 
gene delivery of glutamate transporters may be a viable therapeutic strategy to treat 
neurological disorders involving chronic dysregulation of glutamate. However, the 
amount of time needed for stable expression of the glutamate transporters (~ 3 weeks) 
limits the ability of this technique to treat acute excitotoxicty seen in stroke and TBI. 
Recently, novel activators of GLT-1 have been identified that produce a rapid increase in 
the expression of the transporter within 24 hours (Xing, et al. 2011). Further work should 
examine the potential of these compounds to prevent/limit acute excitotoxicty in stroke 
and TBI animal models.   
Presently, there are no approved therapeutics for the treatment of TBI, instead 
current medical care focuses on maintaining proper physiological parameters such as 
blood pressure and intracranial pressure (ICP) (Wang, et al. 2006). A major problem 
hindering the development of successful therapies into the clinic is an inability to model 
the severity and complexity of severe TBI, which may explain why therapies developed 
and tested in animal models of TBI have failed to show a clinical benefit (Bullock, et al. 
1999). To gain better insight into the physiology of a severe TBI, a multitude of invasive 
neuromonitors have been developed in the past 20 years. These neuromonitors are 
currently being used to detect the pathophysiological mechanisms of severe TBI and find 
a reliable biomarker that could aid in the diagnosis of TBI severity, guide patient care 
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and management, predict functional outcomes, and test the efficacy of therapeutics 
(Kirkpatrick, et al. 1996, Patel, et al. 2002, Stuart, et al. 2010). However, only ICP 
monitoring is currently in the standard of care for management of severe TBI patients 
(The Brain Trauma Foundation, 2000); emphasizing the need for improved tools to 
detect the pathophysiological mechanisms of TBI. 
We hypothesize that enzyme-based microelectrode arrays (MEAs) can provide 
insight into the pathophysiological mechanisms of TBI and detect potential biomarkers to 
guide the care of TBI patients. In chapter Five, we demonstrated the potential of MEAs 
as a novel neuromonitoring device for severe TBI to help understand the 
pathophysiology of TBI and possibly detect a reliable biomarker(s). TBI offers a unique 
platform for translation of MEA technology into the clinic for a variety of reasons. First, 
there is a large amount of evidence from clinical microdialysis studies confirming 
glutamate, lactate, pyruvate, and glucose as potential biomarkers for TBI, 
neurochemicals that MEAs can reliably detect. Second, MEA technology exhibits certain 
methodological advantages compared to microdialysis for in vivo detection of 
neurochemicals in a clinical setting, such as improved spatial and temporal resolution, 
limited damage to the central nervous system, and real-time data readouts at the 
bedside. Third, a multitude of invasive neuromonitors are already being used in severe 
TBI patients, providing a clear path into the clinic with the rationale, protocols, and 
procedures already in place for implantation and recording from these devices. Overall, 
there is a substantial amount of evidence that the care and management of severe TBI 
patients may benefit from translation of MEA technology into the clinic. 
 A tremendous amount of work is still needed to make the translational leap into 
the clinic. We need to design a final clinical prototype with consultation from 
neurosurgeons to ensure practical functionally of the device. Once the devices are 
manufactured, we need to ensure that the probes will remain functional after sterilization. 
Previous work in our lab by Dr. Michelle Stephens has already identified a viable 
sterilization procedure that should be successful (Stephens, et al. 2010). In addition, we 
need to determine if we can improve the reliability of the enzyme coatings allowing the 
performance of the MEAs to be predicted from the initial H2O2 calibration. Using the 
H2O2 calibration prior to enzyme coatings, instead of the traditional glutamate calibration 
that is used prior to implantation in animals, would negate the need for pre-calibrations 
prior to implantation into the central nervous system, which may not be possible in the 
clinical situation. With advice from neurosurgeons and researchers, we need to develop 
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implantation procedures and protocols with a major focus on determining the placement 
of the probe (white/grey matter, normal/peri-lesional tissue) in the various types of brain 
injuries (diffuse, focal, subarachnoid hemorrhage, etc.). Furthermore, parameters or 
tests need to be developed to ensure proper functioning of the device. Lastly, the 
software for readout and analysis of the data needs to be compatible with currently used 
ICU equipment and software. Overall, advancement of MEA technology into the clinic 
may provide insights into the pathophysiology of TBI leading to the development of novel 
drugs, and/or provide a tool that can reliably detect a biomarker to aide in the diagnosis 
of TBI severity, guide patient care and management, predict functional outcomes, and 
test the efficacy of therapeutics, which may lead to improvements in the outcomes of TBI 
survivors. 
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Chapter Six: Figures  
 
Figure 6.1 Schematic depicting the disruptions in the regulation of extracellular 
glutamate in the rat striatum two days after diffuse brain injury 
 
In brain-injured rats, we detected post-traumatic disruptions in the regulation of 
extracellular glutamate that include (1) increased tonic glutamate levels, (2) reduced 
contribution of calcium-dependent glutamate release to tonic glutamate, (3) increased 
amplitudes of evoked glutamate release, (4) slower glutamate clearance primarily due to 
decreases in glutamate. 
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